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Background
In sub-Saharan Africa, human immunodeficiency virus and acquired immune 
deficiency syndrome (HIV/AIDS) is the leading contributor to life-years lost 
(1), causing 1.1 million (73%) of the 1.5 million deaths worldwide due to HIV/
AIDS in 2014 (2). In addition, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) reported that 70% of the 1.5 million new HIV infections worldwide 
occurred in sub-Saharan Africa (2). Only 37% of HIV-infected individuals in sub-
Saharan Africa are receiving life-saving antiretroviral therapy (ART) (3). These 
numbers document the major disproportionate burden of disease inflicted by 
HIV in sub-Saharan Africa, as well as the substantial potential for improvement 
if HIV prevention, diagnosis, and management can be optimized.
In patients who have, or are at risk for, HIV infection, challenges are further 
exacerbated in the setting of overlapping co-infections. For example, sexually-
transmitted infections (STIs) in women not only cause direct morbidity and 
mortality (e.g., chronic pelvic inflammatory disease leading to infertility in 
women and congenital infection in their babies), but they additionally increase 
susceptibility to HIV acquisition (4). Tuberculosis patients who are co-infected 
with HIV have a two-fold higher mortality rate than tuberculosis patients without 
HIV infection (5). Tuberculosis, STIs, and a variety of other co-infections in HIV-
infected patients increase the plasma concentration of HIV RNA (viral load), 
which is well-recognized as a primary marker of HIV transmissibility and disease 
progression. A recent systematic review summarized 18 different studies, all of 
which demonstrated that the viral load could be reduced through appropriate 
treatment of tuberculosis, STIs, malaria, or helminth infections (6). Taken 
together, these examples clearly document the impact of multiple infections on 
the health of an individual, and the importance of investigating ways in which 
co-infections can be managed to improve morbidity and mortality.
This thesis will focus on HIV and parasitic infections caused by Schistosoma 
mansoni and Schistosoma haematobium in Tanzania. It will begin by investigating 
the overlap and interactions between these two highly prevalent infections 
(Chapters 2 and 3). It will then describe the chronic complications related to 
schistosomiasis of the urogenital tract that may increase a woman’s susceptibility 
to HIV acquisition even after treatment (Chapter 4), and will document an 
innovative laboratory technique by which additional studies of the relationship 
between schistosome infection and HIV may be explored using dried blood 
spots (Chapter 5). After this, the focus will turn to a study of the interactions 
of schistosome infection and HIV in HIV-infected individuals who are taking 
antiretroviral medications (Chapter 6). Finally, the thesis will investigate the 
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implementation of better care to improve early infant diagnosis of HIV infection 
in infants born to HIV-infected mothers (Chapter 7). The discussion will focus on 
the knowledge gained through studies to this point, as well as the recommended 
next steps for further research to improve diagnosis, treatment, and disease 
prevention in individuals living in sub-Saharan Africa.
Overview of Schistosomiasis
Schistosomiasis is a parasitic infection caused by helminthic worms of the 
Schistosoma genus. The three main species of schistosomes that cause human 
disease are S. haematobium, S. mansoni, and S. japonicum. The World Health 
Organization (WHO) estimates that, in 2013, over 260 million individuals 
required treatment for schistosomiasis, and that an additional 700 million were 
at risk of infection, with over 90% of these individuals living in Africa where both 
S. mansoni and S. haematobium are endemic (7,8). Schistosomiasis is a disease 
of poverty acquired by contact with fresh water that has been contaminated by 
parasite larvae and is classified as a neglected tropical disease by the WHO (9). 
Schistosomiasis causes a large global burden of morbidity, with an estimated 3.31 
million disability-adjusted life years in 2010. This was second only to leishmaniasis 
(3.32 million) among the neglected tropical diseases (10).
Schistosomiasis has a complicated life cycle that is propagated when the following 
requirements are met: (1) human excrement containing schistosome ova must 
contaminate fresh water; (2) specific intermediate snail hosts must reside in the 
contaminated water; and (3) humans must come into contact with contaminated 
water. Schistosome eggs, excreted into fresh water, hatch to release miracidium 
larvae that seek snail hosts, where they replicate asexually to produce multiple 
generations of sporocysts (11,12). Sporocysts mature into cercariae with a 
characteristic bifurcated tail, and are then released from snails into fresh water to 
seek their definitive host. Cercariae typically live for 24 hours and can penetrate 
unbroken skin, resulting in human infection (11,13). During skin penetration, 
cercariae lose their bifurcated tail and become schistosomulae, which migrate 
through tissue into the host blood stream, the lung, and ultimately the portal 
vein (11,12). Schistosomulae mature in the portal vein for 4-6 weeks into adult 
worms and, once mature, migrate preferentially to venules of the urinary and 
genital tracts (S. haematobium) or the gastrointestinal tract (S. mansoni, S. 
japonicum). 
Adult schistosome worms living in venules form permanent reproductive 
male-female pairs, producing hundreds to thousands of eggs per day and living 
an average of 3-5 years (11,14). Schistosome miracidia within eggs secrete 
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proteolytic enzymes that facilitate the migration of the egg through the vessel 
wall and into the surrounding tissues toward the mucosal tissue and lumen of the 
genitourinary tract or intestine (15). Approximately one-third of eggs produced 
by worms ultimately arrive at the lumen of the bladder or intestine and are 
excreted in urine or stool (14); the remaining eggs are trapped in the tissues or 
are embolized to distant organs. Repeated exposure to schistosome-infected fresh 
water progressively increases the number of worms and eggs and the severity of 
the infection. 
Schistosomiasis causes a plethora of immune alterations in the immune system 
of the host, with effects on T-helper (Th) 1, Th2, Th17, and T-regulatory (T-reg) 
immune responses. The initial immune response to schistosome infection is 
T-helper 1 (Th1)-mediated, directed against worm antigens. Once adult worms 
have matured and egg production begins, the immune response rapidly becomes 
T-helper 2 (Th-2)-mediated due to the high antigenicity of eggs as they migrate 
through tissue (16). This Th2-type response leads to granulomatous inflammation 
that surrounds eggs trapped in tissue, and, ultimately, to tissue fibrosis and 
chronic morbidity (17). This granulomatous response is paradoxical in its effect: 
though it does incite tissue fibrosis, it also protects the host tissue by sequestering 
toxic secretions of schistosome eggs that can otherwise result in widespread host 
tissue necrosis (16,18,19). Prolonged infection with granulomatous changes lead 
to late-stage tissue obstructive changes. Interestingly, such obstructive changes 
have been associated with increased tissue burdens of eggs in autopsy studies, 
suggesting that late-stage fibrosis may decrease transmission of the parasite from 
the index case (20,21). 
A natural history study of morbidity caused by S. haematobium in an endemic 
region of Kenya supports this progression of tissue pathology over time (20). 
Investigators demonstrated that, in the initial years of infection, urinary tract 
lesions were inflammatory granulomata of the ureters or bladder. Over time, 
these lesions progressed to “established” or obstructive tissue changes such 
as hydronephrosis, hydroureter, and bladder fibrosis. The study investigators 
suggested that, because hydronephrosis predominantly affected adults and 
appeared to be independent of intensity of schistosome infection, the duration of 
parasite infection more accurately predicts risk of chronic tissue disease than the 
intensity of infection. Multiple studies have also demonstrated the importance of 
other factors including treatment, reinfection, and a complicated interplay of host 
genetics influencing the balance of Th1, Th2, Th17, and T-reg-type reactions to 
the parasite eggs in determining the degree of tissue damage and host pathology 
(11,17,22,23). 
Chapter 1  13
The major morbidity experienced in chronic schistosomiasis is attributable to 
the host’s egg-induced granulomatous response and subsequent fibrosis in the 
bladder, intestine, and liver (24). Prominent clinical sequelae of various species 
of schistosomes depend largely on where adult worms reside. S. haematobium 
worms live in venules surrounding the urinary and genital tracts, and thus their 
migrating eggs typically cause bladder/ureter fibrosis leading to hydronephrosis, 
bladder cancer, and genital tract damage including erosions, edema, sandy 
patches, and neovascularization of the cervix, as well as alterations in immune 
cell populations in the genital mucosal tissue (25–28). Major sequelae of S. 
mansoni infection include diarrhea, intestinal inflammation, and liver fibrosis 
leading to esophageal varices and hematemesis. A 2003 paper estimated the 
annual global mortality from renal failure secondary to S. haematobium to 
be 150,000 and from hematemesis induced by S. mansoni to be 130,000 (29). 
Morbidity is also significant in those with chronic schistosome infection, who 
suffer from significantly higher burdens of anemia, poor nutrition, pain, and 
impaired academic performance and have been estimated to function at a 
disability level of 2-15% (30).
The gold standard for diagnosis, recommended by the WHO, is microscopic 
visualization of parasite eggs in urine or stool (8). Urine is filtered through a 
porous membrane filter through which schistosome eggs cannot pass, and the 
filter is examined directly under the microscope. Urinary infection intensity is 
reported as eggs per 10 milliliters (ml) of urine. Eggs in stool can be quantified 
using the Kato Katz technique, in which a thick fecal smear of known mass is 
prepared, stained, and examined for schistosome ova. Stool infection intensity 
is reported as eggs per gram (epg). It is well-recognized that egg excretion varies, 
particularly in those with light infections, and that this gold standard may be 
less sensitive than other diagnostic strategies including antigen testing and 
polymerase chain reaction (PCR) (31–33). 
A highly promising diagnostic strategy is the detection of schistosome circulating 
antigens, which is used for much of the work done in this thesis. Circulating 
anodic antigen (CAA) and circulating cathodic antigen (CCA) are produced 
in the gut of schistosome worms and regurgitated by the worm into the host 
bloodstream during active infection with either S. mansoni or S. haematobium 
(34). CAA becomes detectable in serum approximately 3 weeks after infection (35). 
It is heat-resistant and extremely stable, remaining detectable in tissue isolated 
from Egyptian mummies (36) and in dried blood spots (37). CAA levels fall 
rapidly post-treatment, with a serum half-life of 2 days, becoming undetectable 
within 3-6 weeks (38,39) and become positive again with reinfection (40). The 
CAA assay is recommended by the WHO for serologic screening programs in 
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which repeated parasitologic examinations of urine and stool are logistically not 
possible (36,41,42). CAA testing has been optimized using up-converter phosphor 
technology with dry reagents that are robust and straightforward for use (43,44). 
CCA testing has been developed into a commercially available point-of-care rapid 
test with high sensitivity and specificity for S. mansoni, though its performance 
for S. haematobium diagnosis is less reliable (44–47).
Schistosome infections occur often and early in endemic areas, beginning with 
babies and preschoolers and typically increasing in both prevalence and intensity 
throughout childhood, pea-
king during adolescence, 
then diminishing slowly 
as adults acquire partial 
but incomplete immunity 
(11,48–50). Our prior work 
has demonstrated that 
significant proportions of 
both young and middle-aged 
adults remain chronically 
infected in endemic areas 
(Figure 1). The WHO 
schistosomiasis treatment 
guidelines focus primarily 
on children, recommending 
that all children in high-
risk communities should 
treated annually with the 
antihelminthic drug praziquantel, at an estimated cost of USD $0.32 per dose 
(51,52). Treatment is additionally extended to adults at special risk (such as those 
occupationally exposed to water or women using water for domestic chores) and 
to entire communities in endemic areas (51). In the real world, such treatment 
is a challenge, and the usual practice in Tanzania is to provide school-based 
praziquantel treatment for children annually, with no routine treatment after 
that. The WHO estimates that, in 2013, only 13% of those who needed treatment 
for schistosomiasis actually received praziquantel (8). 
Thus it is clear that major implementation gaps remain and millions of children 
and adults continue to live with the chronic burden of untreated schistosomiasis. 
Moreover, in the absence of improved access to clean water, many individuals 
living in schistosome-endemic areas have no choice but to continue to use unclean 
water in order to sustain their livelihood. The result is a lifetime of chronic 
Figure 1. Proportion of schistosome infections by age 
among 477 rural Tanzanian adults living in villages 
highly endemic for schistosomiasis.
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schistosome infection and suboptimal health endured by millions of individuals 
living in sub-Saharan Africa.
The Confluence of Schistosomiasis and HIV Infection in sub-Saharan 
Africa
Approximately 78 million individuals have been infected by HIV since the 
epidemic began, and 35 million people are currently living with HIV worldwide 
(53). The HIV epidemic arose in sub-Saharan Africa and over 70% of global 
HIV infections (over 24 million) remain in this region (2,54). Epidemiologic 
mapping of HIV and schistosomiasis reveals a substantial overlap between areas 
in which both schistosomiasis and HIV are epidemic (Figure 2). In Tanzania, 
the prevalence of schistosomiasis in many areas is >50%, and the prevalence of 
HIV is 5.1% (55).
Country-level epidemiologic data also suggests a relationship between 
schistosomiasis and HIV infection. A recent regression analysis used publicly-
available data to determine the relationships between HIV infection, schistosome 
infection, and other epidemiologic and demographic data. Investigators reported 
that, after adjusting for other factors associated with HIV prevalence including 
male circumcision prevalence, years since the HIV epidemic began in a country, 
and immunization coverage, each one additional case of S. haematobium per 100 
people was associated with a 2.9% (95% confidence interval (CI), 0.2% - 5.8%) 
Figure 2. Schistosomiasis and HIV epidemics in Africa.
Schistosomiasis
World Health Organization, 2012
HIV Prevalence in Adults Aged 15-49
UNAIDS and Kaiser Family Foundation, 2014
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relative increase in the prevalence of HIV infection (56). While this data is cross-
sectional and therefore not able to determine causality or to exclude potential 
confounders, it does lend plausibility to the existence of a relationship between the 
two infections.
In further support of the HIV-schistosomiasis association, the first cross-sectional 
study performed in individual patients was published in 2006 by Kjetland and 
colleagues. The study, which enrolled 527 women living in a region in Zimbabwe 
in which S. haematobium was highly endemic (with 43% of the overall study 
population having S. haematobium ova detected in urine or genital specimen), 
demonstrated that women who had S. haematobium ova found in a cervical 
Pap smear had a higher prevalence of HIV infection than those without ova in 
a Pap smear, with an adjusted odds ratio (OR) of 2.9 [95% CI, 1.1-7.5] (p=0.030) 
(57). Other measured factors significantly associated with HIV on multivariable 
analysis included Herpes Simplex Virus-Type 2 (HSV-2) infection, widowhood, 
infertility, and age. Investigators subsequently followed 224 women for 12 months 
and documented 7 new HIV seroconversions; all 7 of these occurred in women 
who had had signs of urogenital schistosomiasis at baseline, compared with 
142/217 who had had signs of urogenital schistosomiasis at baseline but remained 
negative (p=0.098). 
Though others had previously speculated that genital S. haematobium infection 
may predispose to HIV due to its ability to cause genital ulcer disease (25,58), 
the study from Zimbabwe was the first and, at the time of its publication, the 
only clinical study to demonstrate a clear association between the two infections. 
While the study design did not permit determination of causality, investigators 
postulated that S. haematobium genital infection, typically acquired during 
childhood prior to HIV exposure, could increase a woman’s susceptibility to HIV 
infection. Chapters 2 and 3 of this thesis document additional clinical studies 
from Tanzania that were conducted to quantitate the relationship between 
schistosomiasis and HIV infection in women.
Urogenital Schistosomiasis: a Risk Factor for HIV Acquisition?
Formerly termed “urinary schistosomiasis,” S. haematobium infection was 
renamed “urogenital schistosomiasis” in 2009 by the WHO in recognition that up 
to 75% of individuals with S. haematobium infection have both bladder and genital 
tract involvement (59). S. haematobium worms reside in venules surrounding the 
urinary bladder and pelvic organs, and schistosome ova become sequestered in 
the not only the bladder and ureters, but also throughout both the female and male 
reproductive tracts (Figure 3). Post-mortem and surgical studies have confirmed 
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that, in women, the cervix is 
the most common site of ova 
sequestration, followed by vagina 
and Fallopian tubes (60). Eggs 
lodged in genital sites provoke 
signs and symptoms including 
pelvic discomfort, postcoital 
bleeding, itching, and vaginal 
discharge in women and painful 
ejaculation, hematospermia, 
and leukocytospermia in men 
(25,26,61–63). Findings on 
clinical examination in women 
include edema of the cervical 
or vaginal mucosae, erosions, 
ulcerations, neovascularization, 
and mucosal friability (26,28). 
These breaches in the epithelial 
integrity of the female genital 
tract, similar to those caused by 
trauma or STIs, have been suggested to enhance the ease of viral entry beneath 
the surface of the genital epithelium, thereby facilitating HIV acquisition in 
women with schistosomal cervical damage (25,64).
Schistosome ova sequestered in genital tissue cause a spectrum of clinical pathology, 
which are best visualized using a colposcope and are used by some to make a clinical 
diagnosis of urogenital schistosomiasis since detection of ova or parasite DNA in 
genital secretions and tissues can be challenging (65,66). Classic schistosome-
induced lesions of the genital mucosa have recently been photographically detailed 
in a “Colposcopic Atlas of Schistosomiasis” that is intended to serve as a diagnostic 
guidebook for clinicians and researchers (67). “Grainy sandy patches,” which 
are rough grains located superficially within the genital mucosa that represent 
calcified ova beneath an atrophic epithelium, are pathognomonic for urogenital 
schistosomiasis (26). Another lesion, the “homogeneous yellow sandy patch,” can 
be identified both in women with S. haematobium infection and in those with STIs, 
making this finding less specific. Sandy patches are often surrounded by abnormal 
blood vessels with diffuse inflammation and contact bleeding (67). The contact 
bleeding may provide an additional mechanism—direct access of the virus to fresh 
blood—by which HIV risk could be increased in the presence of S. haematobium 
infection. Importantly, sandy patches and vascular abnormalities appeared not to 
be completely reversible following praziquantel treatment in women (68,69). This 
Figure 3. Schistosoma haematobium ova obtained 
in a crushed cervical biopsy (performed to exclude 
cervical cancer) from a 24-year-old woman in rural 
Tanzania.
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suggests that schistosome ova in tissue could cause longstanding and possibly 
permanent effects, particularly in women who are not treated until they are older 
than age 20 (70).
Finally, at the cellular level, schistosome ova in tissue induce a complex immune 
response that is characterized by infiltration of plasma cells, lymphocytes, 
macrophages, and eosinophils to the genital tract (71). Jourdan and colleagues 
quantified HIV-susceptible cells in cervicovaginal biopsies from Malawian 
women with and without S. haematobium ova and found that biopsies containing 
ova had higher densities of CD4+ T-lymphocytes and macrophages than biopsies 
without ova (27). These cellular changes at the tissue level also appear to be 
reflected systemically in the peripheral blood of infected individuals. In Kenya, the 
monocytes and CD4+ T-cells of car washers with S. mansoni infection exhibited 
higher densities of the chemokine receptors CCR5 and CXCR4 than the monocytes 
and CD4+ T-cells of those who had been treated for schistosomiasis (72). Because 
CCR5 and CXCR4 are also HIV co-receptors, investigators postulated that the 
monocytes and CD4+ T-cells from individuals with schistosome infection may 
be more susceptible to HIV infection than these same cells in uninfected or 
previously-treated individuals. Further, the tendency of schistosome infection to 
incite a Th2-type response, with an accompanying shift away from the cytotoxic 
Th1-type immunity that is critical to the early antiviral defense against HIV, may 
also promote an immune environment that is more permissive to HIV acquisition 
(64,73).
Taken together, the apparent interactions between HIV and schistosomiasis 
across a breadth of lines of investigation, and the biologic plausibility of such an 
association, lends credence to the hypothesis that schistosomiasis may increase 
susceptibility to HIV acquisition. Furthermore, the effects of schistosomiasis may 
not be reversible with treatment, leading to chronic enhanced HIV susceptibility. 
The two studies that explored response of urogenital schistosomiasis to 
praziquantel treatment documented clinical and parasitological findings, but did 
not use molecular techniques and therefore relied on tests with poorer negative 
predictive value to indicate whether the parasite had been eradicated or whether 
infection persisted. Confirming and extending these prior studies using molecular 
diagnostics was the goal of the longitudinal work described in Chapter 4.
The other clear need that emerges from this review of the relationship between HIV 
and schistosomiasis is the need for prospective studies that are able to document 
conclusively that pre-existing schistosome infection is a risk factor for incident 
HIV infection. Such longitudinal studies are complex and fraught with ethical 
issues, including the gynecological examination of pre-adolescent and adolescent 
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girls and/or the need to follow a group of individuals with known, untreated 
schistosome infection to determine whether the incidence of HIV is higher than 
in those without schistosome infection. One possible idea to circumvent these 
ethical challenges would be to use serum schistosome antigen tests in order to 
analyze banked serum from prior HIV-seroincidence cohorts. We have access to 
stored serum samples from an HIV-seroincidence cohort of 30,000 individuals in 
rural Tanzania who have been followed since 1994. The serum was stored in the 
form of dried blood spots (DBS) on Whatman 903 ProteinSaver cards. Two prior 
papers sought to elute CAA from two other types of filter paper and demonstrated 
that CAA was indeed detectable, but that available concentrations were low (37,74). 
Therefore, the goal of the work described in Chapter 5 was to optimize detection 
of CAA in Whatman 903 cards, which are the most widely-used cards for dried 
blood spot collection worldwide. This would facilitate diagnosis of schistosomiasis 
in a variety of studies in which DBS were collected, and would pave the way for 
analysis of the incidence of HIV among individuals who were and were not CAA-
positive prior to their HIV-seroconversion in our Tanzanian cohort.
Schistosomiasis and HIV Disease Progression in Co-Infected 
Individuals
Studies of HIV-infected individuals with schistosome co-infection demonstrate 
that schistosomiasis may exert some effect on HIV disease progression and 
outcomes. In particular, meta-analyses published in 2008 and 2010 suggested, 
though not conclusively, that the treatment of helminthic infections (75) and 
of helminthic plus other co-infections (6) may decrease HIV viral load. These 
analyses were limited by the dearth of randomized controlled trials and other 
methodological problems in the existing studies on this issue. 
Kallestrup and colleagues conducted the single randomized trial that explored the 
effect of schistosomiasis treatment on viral loads in Zimbabwe, and they reported 
significant viral load differences in treated and untreated groups. In this study, 
antiretroviral therapy (ART)-naïve HIV-infected patients with schistosome co-
infection were randomized to receive single-dose praziquantel either at enrollment 
or after three months. Those randomized to delayed praziquantel treatment 
had greater increases in HIV viral loads and greater decreases in CD4 counts 
than those treated immediately (76). Treatment effectiveness was not reported 
in this population. More recently, a nonblinded, randomized trial of empiric 
albendazole and praziquantel in over 900 Kenyan HIV-infected patients found no 
effect of antihelminthic treatment on CD4 counts, viral loads, time to initiation 
of antiretroviral therapy (ART), or mortality (77). Of note, the prevalence of 
schistosomiasis in this study population was only ~5%, and the study was not 
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designed or powered to detect the effect of treating individual helminth species. 
In the wake of these conflicting findings, unanswered questions remain about 
the impact, or lack of impact, of schistosome co-infection on HIV disease 
progression. Moreover, both the Zimbabwean and the Kenyan trials enrolled 
only HIV-infected patients who had not yet initiated ART. To the best of our 
knowledge, no studies had been done to assess the impact of schistosomiasis on 
the response to ART, which is becoming increasingly relevant as ART coverage in 
sub-Saharan Africa continues to rise, recently reaching above 35% (3). Therefore, 
the work in Chapter 6 was conducted to investigate, for the first time, the effect of 
schistosome infection among HIV-infected individuals who were receiving ART 
in Tanzania.
The Need for Implementation Science Research to Promote Early HIV 
Diagnosis in Tanzania
The 1.4 million new HIV diagnoses occurring annually in sub-Saharan Africa, 
together with the fact that less than 50% of people living with HIV in the region 
are aware of their infection status (3), demonstrate the ongoing need for major 
population-based interventions to prevent HIV altogether and to diagnose it 
expeditiously. Even when cost and logistics are not limiting factors, the journey 
from awareness of evidence-based best practices to implementation of these 
practices can be challenging. Religion, cultural values, education levels, health 
beliefs, and social norms all impact a person’s, or a population’s, willingness to 
adopt practices, even those that have been scientifically proven to be beneficial for 
health. Challenges are often exacerbated in resource-poor settings. 
The growing field of implementation science strives to address these issues. 
Implementation science seeks to determine effective strategies by which research 
findings can be incorporated into healthcare policy and practice in specific 
settings in order to improve population health (78). The final chapter of this 
dissertation, inspired by the experience of spending years living and working in 
a country in which healthcare providers struggle to implement evidence-based 
guidelines, is such an implementation science study. This chapter focuses on 
issues related to implementing practices that, although known to be effective in 
early infant diagnosis of HIV, have faced implementation obstacles in Tanzania.
Chapter 7 is an implementation science project, conducted in rural Tanzania, that 
focused on streamlining early infant diagnosis (EID) of HIV infection in infants 
who were exposed perinatally to HIV. Early diagnosis is urgent because infants 
who become HIV-infected before, during, or shortly after birth have a mortality 
rate of approximately 50% before 12 months of age, with 20% dying before they 
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reach 3 months of age (79). In resource-poor areas without local laboratory 
facilities able to perform the PCR necessary to detect HIV RNA or DNA in an 
infant’s blood, the WHO recommends collecting blood as DBS and shipping 
them to a reference laboratory with PCR capacity (80). Bugando Medical Centre 
in Mwanza, Tanzania houses the reference laboratory for 13 million people, and 
receives DBS for EID from 96 clinics in the region. Returning an HIV test result 
to an infant’s mother typically takes weeks because the testing system depends 
on a multi-step process in which DBS are collected, transported to the laboratory, 
tested at the laboratory, returned to the clinic, and then communicated to the 
mother. This implementation science work was prompted by the observation 
that many mothers were never receiving their infants’ test results, and those who 
did were receiving them extremely late. The implementation science research 
described in this chapter used a systems improvement methodology to make 
sequential interventions in this multi-step process and to monitor the effects of 
these interventions. 
Finally, in the general discussion in Chapter 8, the key findings from the 
preceding chapters will be analyzed, and the contribution that these findings have 
made to the knowledge base will be summarized. We will close each section of the 
discussion by outlining logical next research steps to explore research questions 
that remain.
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Abstract
We conducted a community-based study of 457 women aged 18--50 years living 
in eight rural villages in northwest Tanzania. The prevalence of female urogenital 
schistosomiasis (FUS) was 5% overall but ranged from 0 to 11%. FUS was 
associated with HIV infection (OR = 4.0, 95% confidence interval: [1.2--13.5]) 
and younger age (OR = 5.5 [1.2--26.3] for age < 25 years and 8.2 [1.7--38.4] for 
age 25--29, compared to age > 35). Overall HIV prevalence was 5.9% but was 
17% among women with FUS. We observed significant geographical clustering 
of schistosomiasis: northern villages near Lake Victoria had more S. mansoni 
infections (p < 0.0001), and southern villages further from the lake had more 
S. haematobium (p = 0.002). Our data support the postulate that FUS may be a 
risk factor for HIV infection, and may contribute to the extremely high rates of 
HIV among young women in sub-Saharan Africa.
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Introduction
Female urogenital schistosomiasis (FUS) is predominantly caused by Schistosoma 
haematobium and has been estimated by the World Health Organization 
(WHO) to affect up to 45 million women living in sub-Saharan Africa.1 Adult S. 
haematobium worms inhabit blood vessels surrounding the urinary bladder and 
female genital tract and lay eggs that migrate through tissue of proximate organs, 
causing chronic granulomatous inflammation most commonly in the urinary 
bladder, ureters, cervix, and vagina. Because the urinary and genital tracts 
are almost always both affected, the WHO has recently renamed this disease 
“urogenital schistosomiasis,” with detection of S. haematobium in the urine or 
genital tract diagnostic.1  
Chronic female genital tract inflammation caused by S. haematobium has been 
associated with vaginal itching and discharge,2 postcoital bleeding,3 genitopelvic 
discomfort,4 marital discord,5 and infertility.6,7 Genital S. haematobium infection 
has been associated with HIV infection in one cross-sectional study7 and has 
been postulated to be a risk factor for HIV infection.8,9 
Tanzania’s Lake Victoria region in northwestern Tanzania borders Kenya, 
Uganda, and Rwanda and is believed to have among the highest prevalence of 
S. haematobium in the world, with a prevalence of 50--90% reported in young 
schoolchildren.10 The prevalence of S. haematobium infection has not been 
quantified in women of reproductive age, the population at risk for increased HIV 
infection. Therefore, we conducted a study in Tanzania’s Lake Victoria region 




Study sites and subjects. This cross-sectional study was conducted between 
August 2009 and May 2010 near Lake Victoria in northwest Tanzania in 
partnership with a cervical cancer screening program being conducted at local 
health centers. Women who were receiving free cervical cancer screening, were 
between the age of 18 and 50 years, and who provided written consent were invited 
to participate in the FUS prevalence study. Women who were menstruating or 
who refused gynecologic examination were excluded. Pregnant and breastfeeding 
women were included.
Urine and gynecologic examination. A single urine sample was collected from 
women between 10am and 2pm and filtered and examined microscopically by a 
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trained parasitologist for schistosomal ova. A subset of the urine samples were 
read by two parasitologists for quality control.
Women who provided informed consent underwent a gynecological examination. 
A swab of vaginal secretions was collected for wet preparation and microscopic 
examination for diagnosis of Candida (using a potassium hydroxide preparation), 
Trichomonas vaginalis (using warm normal saline), and bacterial vaginosis by 
Amsel’s criteria.11 Next, a cervical smear was collected using a plastic spatula. 
Smears were stained with 0.5% Trypan Blue and were examined for schistosomal 
ova while fresh. Acetic acid was then applied to the face of the cervix, followed 
by inspection for abnormal areas after one minute. Abnormal cervical lesions 
were biopsied. Specimens were stained with Hematoxylin and Eosin (H&E) for 
histopathological examination and with Trypan Blue to examine for schistosomal 
ova using the “crush technique” previously described.6,12 Biopsies were not 
performed on pregnant women.
Female urogenital schistosomiasis (FUS) was defined following WHO criteria as 
the presence of at least one schistosomal ovum seen in the urine sample, cervical 
smear, or cervical biopsy.1
Other laboratory studies. Single stool samples for S. mansoni ova were processed 
by Kato Katz technique. HIV voluntary counseling and testing was offered to all 
participants. For those who agreed to be tested, blood was collected and tested 
using a rapid test (SD Bioline). Testing was performed in the field and patients 
received their results immediately. Venous blood was also collected and tested 
for syphilis using the Rapid Plasma Reagin (RPR) test and positive tests were 
confirmed with the Treponema pallidum Particle Agglutination assay (TPPA).
Interview. Women also participated in a 20-minute structured interview 
about water contact, gynecologic symptoms, sexual history, and depression. 
The interview was administered by a nurse in Kiswahili. Women were asked 
to use a 4-point Likert scale to quantify how much, over the past four weeks, 
they had been bothered by dyspareunia, vaginal discharge, postcoital bleeding, 
abdominopelvic pain, infertility, menstrual abnormalities, genital itch, and 
incontinence. Using a 5-point Likert scale to assess sexual dysfunction, women 
were also asked how much they worried about pain during intercourse, made 
excuses to avoid intercourse, had experienced decreased frequency or quality 
of intercourse, and were concerned about partner infidelity. We assessed the 
responses to these questions as binary variables, where answers of “very much” 
or “somewhat” were considered positive, while answers of “rarely” or “not at all” 
were considered negative.
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Depression was evaluated using a 9-item depression scale, the PHQ-9, that has been 
previously translated and validated in Kiswahili in several patient populations.13,14 
The PHQ-9 consists of nine questions, each designed to assess for one of the nine 
symptoms of depression delineated by the Diagnostic and Statistical Manual-IV 
(DSM-IV) for depression. These include anhedonia, sleeplessness or excessive 
sleep, hopelessness, poor or excessive appetite, difficulty concentrating, and 
feelings of failure. Participants receive between 0 and 3 points on each question, 
with 0 indicating that they experienced a given symptom “Not at all” and 3 
indicating “Nearly every day”.  A total score of 5--9 has been classified as mild 
depression, 10--14 indicates moderate depression, 15--19 indicates moderately-
severe depression, and above 20 indicates severe depression.15
Ethical considerations. The study was explained to women in a large group and 
subsequently one-on-one by a trained study nurse fluent in the local language. 
In order to participate in the study, women were asked to provide written 
informed consent or to place their mark on the consent form. At the local level, 
permission was obtained from the District Medical Officers and clinicians 
stationed at participating dispensaries and health centers. Ethical approval 
was granted by the research ethics committee at Bugando Medical Centre, by 
the Medical Research Coordinating Committee of the National Institute for 
Medical Research in Tanzania, and by the Institutional Review Board at Weill-
Cornell Medical College. 
Women diagnosed with urogenital or intestinal schistosomiasis, syphilis, 
trichomoniasis, candidiasis, or bacterial vaginosis received free treatment. 
Women with trichomoniasis were given medication both for themselves and their 
sexual partners. Women with syphilis and their sexual partners received three 
intramuscular injections of penicillin at the clinic. Patients diagnosed with HIV 
were referred to nearby district or regional hospital-based clinics for free care 
and treatment. Women with cervical dysplasia or cancer were referred to tertiary 
institutions for further management, and all of them accessed care successfully.
Statistical methods. Data were entered into a REDCap database (Vanderbilt 
University, Nashville, Tennessee). Continuous variables were summarized by 
median and interquartile range and categorical variables were summarized 
by frequency and percentage. Regional disparity of infections was assessed by 
Fisher’s exact test; the association of infection status and region was evaluated 
using northern versus southern designation (in a 2 x 2 table) as well as individual 
regions (in a 2 x 8 table). Factors that were associated with the endpoint (i.e., 
FUS) were examined by multiple logistic regression. Backward elimination was 
adopted to reach the final parsimonious model that included significant factors 
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only – starting from a full model with all of the candidate predictors (all factors 
presented in Tables 1 and 3) and deleting the least significant factor one at 
a time until only the predictors with p-value < 0.05 remain in the model.  We 
also confirmed that the automatic variable selection procedures (e.g., stepwise, 
forward, backward selection) yielded the same final model. We analyzed age 
in two different ways – using a continuous variable and categorized variables 
(with 25, 30, and 35 as cutoff points, which approximately corresponded to lower 
quartile, median and upper quartile, respectively).
Association between factors and the endpoint was summarized in odds ratio 
(OR) along with 95% confidence interval (CI) and the associated p-value. We 
also computed the area under the receiver-operating-characteristic curve (AUC) 
to ascertain the discrimination capability of the factors for FUS cases vs. non-
cases—AUC of 0.5 means that the discrimination capability is no better than 
chance, and 1 means perfect discrimination.
SAS 9.2 (Cary, North Carolina) was used for data analyses. Two sided hypotheses/
tests were assumed for computation of all confidence intervals and p-values.
Results
Patient Characteristics. Out of 550 eligible women who presented to primary 
care clinics and were invited to participate in the study, 457 women (83.1%) 
consented to participate and completed all study procedures. Characteristics of 
study participants are shown in Table 1. The median age was 30 years (IQR, 24-
-35 years). The great majority was married, had at least one child, and worked in 
farming and petty trade. Participants had a median number of 14 contacts with 
potentially-infectious water per day, and no woman reported zero contacts. One-
third reported receiving treatment for schistosomiasis in the past.
Prevalence of Schistosoma haematobium and mansoni infections. The preva-
lence rates for S. haematobium and S. mansoni are presented in Table 2, and a 
map of the area with the villages where screening took place is shown in Figure 
1. The prevalence of S. haematobium infections was higher among women 
living in southern inland villages than in northern villages along the shores of 
Lake Victoria. The prevalence in the south was 13/120 (10.8%) compared with 
10/337 (3%) in women who lived in northern lake-side villages (p = 0.002). Of 
the 23 women with urogenital schistosomiasis included in the analysis, 16 had S. 
haematobium ova detected in the urine only, 6 had S. haematobium ova detected 
in a genital specimen, and one had S. mansoni ova visualized on a cervical smear.
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TABLE 1. Baseline characteristics of 457 women attending primary care 
clinics for schistosomiasis screening in Mwanza, Tanzania.
CHARACTERISTIC VALUE
Age in years—median (interquartile range) 30 (24--35)
Marital Status—number (percent)
   Single
   Living with partner
   Married
   Divorced






Having at least one child—number (percent) 415 (90.8%)
People living in household—number (percent)
   0--4
   5--7 
   8--10






     Agriculture and/or petty trade
     Homemaker




Went to bed hungry in past month—number (percent) 27 (5.9%)
Number of water contacts per dayb-- median (interquartile 
range)
14.1 (11.4--17.0)
Ever treated for schistosomiasis—number (percent) 159 (34.8%)
Received an artemesinin-containing medication for malaria 
in the past 3 years—number (percent)
163 (35.7%)
aPercentages were calculated using a denominator of the total sample size, 457. 
Missing data are present in some variables (with < 7%). Age was missing in 6 
women and water contact data was missing in 21 women.
bWater contact behaviors combined the following information (swimming, 
bathing oneself or a child, washing clothes, hands, animals, or dishes, collecting 
water for use in the home, fishing, using water for crops, wading water to cross it, 
and cultivating rice) by summing their frequencies and dividing by 30.
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S. mansoni infection, by contrast, was only detected among women living in 
northern villages near the lake. Among 337 women living in northern lake-side 
villages, 31 (12.2%) were infected with S. mansoni, and among 120 women in 
southern inland villages, none was infected (p < 0.0001).
Prevalence of other infections. Of the 457 women examined, 33 had bacterial 
vaginosis (7.2%), 22 had candidiasis (4.8%), and 15 had trichomoniasis (3.3%). 
Twenty-seven women were HIV-infected (5.9%), and 33 had reactive syphilis 
serology (7.2%).
Prevalence of gynecologic symptoms, sexual dysfunction, and depression. 
Gynecologic symptoms reported most commonly by women included 
abdominopelvic pain (75.5%), menorrhagia (56.0%), genital itching (54.5%), 
dysmenorrhea (54.3%), dyspareunia (42.9%), and foul-smelling discharge (31.1%) 
(Table 3). The majority of women stated that they made excuses to avoid sexual 
intercourse (66.1%), and 40.9% of women were worried that their partner would 
have sexual relations outside of the relationship. Notably, 77% of women met 
Figure 1. Map of Mwanza region in Tanzania’s Lake Victoria zone with village 
locations. Northern villages nearer to Lake Victoria, with lower rates of S. 
haematobium and higher rates of S. mansoni, are depicted with yellow dots. 
Southern villages, with higher rates of S. haematobium and no S. mansoni infection 
detected, are depicted with red dots.



















LENCE OF  
S. MANSONI
Northern Villages





Nyehunge 75 9 (12%)      6 (8.0%) 12 (16.0%)
Sengerema 
town
71 2 (2.8%)      1 (1.4%) 12 (16.9%)
Kagunga 30 2 (6.7%)      1 (3.3%) 1 (3.3%)
Badugu 23 4 (17.4%)      0 0
Igaka 71 3 (4.2%)      2 (2.8%) 8 (11.3%)
Southern Villages






75 2 (2.7%)      8 (10.7%) 0
P-valuea      0.01 < 0.0001b 0.002 < 0.0001
TABLE 2. Prevalence of Schistosomiasis and HIV in Eight Villages in the 
Mwanza Region of Tanzania’s Lake Zone.
 
aAll p-values were computed by Fisher’s Exact Test.
bFor this specific p-value, Monte Carlo estimation of exact p-values instead of 
direct exact p-value computation was used due to time and memory problems 
encountered for exact computations.
criteria for depression based on the PHQ-9 scale. Of the 457 women, 259 (57%) 
were mildly depressed and 92 (20%) had moderate to severe depression. 
Factors Associated with FUS.  We examined associations between baseline 
characteristics, other infectious diseases, and female urogenital schistosomiasis. 
Younger age was significantly associated with FUS. As a continuous variable, 
age in years showed an odds ratio of 0.92 (95% CI 0.86--0.98), which may be 
interpreted as approximately an 8% decrease in odds of disease per one year 
increase in age. As a categorized variable, age had an odds ratio of 5.5 [95% CI 
1.2--26.3] for women who were younger than 25 years old, 8.2 [95% CI 1.7--38.4] 
for those who were 25--29 years old, and 1.2 [95% CI 0.16--8.4] for those who were 
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TABLE 3. Prevalence of Gynecologic Symptoms, Sexual Dysfunction, and 




    Post-coital bleeding 24 (5.3%)
    Dyspareunia 196 (42.9%)
    Difficulty becoming pregnant 91 (19.9%)
    Abdominal/pelvic pain 345 (75.5%)
    Irregular menses 180 (39.4%)
    Dysmenorrhea 248 (54.3%)
    Genital itching 249 (54.5%)
    Menorrhagia 256 (56.0%)
    Urinary incontinence 41 (9.0%)
    Foul-smelling vaginal discharge 142 (31.1%)
Sexual Dysfunction:c
    Fearful of pain during sexual intercourse 291 (63.7%)
    Makes excuse to avoid sexual intercourse 302 (66.1%)
    Decrease in quality or frequency of sexual relations 242 (53.0%)
    Worry that partner will have sexual relations outside of 
     relationship
187 (40.9%)
Score on Depression Scale:
    No depression (0--4 points) 48 (10.5%)
    Mild depression (5--9 points) 259 (56.7%)
    Moderate depression (10--14 points) 85 (18.6%)
    Moderately severe or severe depression (≥ 15 points) 7 (1.5%)
aPercentages were calculated using a denominator of the total sample size, 457, in 
order to capture existing symptoms. Depression score was missing for 58 women, 
while less than 5.5% of data was missing for all other variables.
bIncludes women that answered they were “somewhat” or “very much” bothered 
by symptom.
cIncludes women that answered “I agree” or “I agree completely” that they 
experience the symptom.
Chapter 2  39
30--34 years old, compared to women who were 35 years old or older (reference 
group). 
HIV was also significantly associated with FUS with an odds ratio of 4.0 [95% CI 
1.2--13.5]. Of the 23 women with FUS, 4 (17.4%) were HIV-infected, compared with 
23 (5.3%) of the 434 women without FUS. There were no significant differences 
among women with and without FUS in the overall rates of other vaginal or 
sexually-transmitted infections including candidiasis, trichomoniasis, bacterial 
vaginosis, or syphilis, and no other significant differences in other variables. The 
final regression model with the two risk factors—age and HIV status—resulted 
in AUC of 0.732 (age as continuous variable) and AUC of 0.72 (age as categorical 
variable), which are much higher than null value of AUC = 0.5. 
Discussion
Female urogenital schistosomiasis affects young women, is associated with HIV 
infection, and is prevalent in inland villages of the Lake Victoria region of Tanzania. 
Our study builds on the findings of a previous study in Zimbabwe, which showed 
an association between HIV infection and Schistosoma haematobium detected 
in cervical specimens with an odds ratio of 2.9 [95% CI 1.2--3.5].7 The authors 
of the earlier study postulated that genital schistosomiasis may predispose to 
HIV infection. Our work extends this finding by demonstrating an association 
between HIV infection and the newly-expanded WHO case definition of 
urogenital schistosomiasis. This finding, in light of the high prevalence of FUS 
in women of reproductive age, may have important public health implications for 
prevention of HIV infection.
While a causal association between FUS and HIV infection will require a 
prospective longitudinal study, a number of factors support the hypothesis 
that the risk of HIV acquisition is augmented by the presence of FUS. First, 
schistosomal infection is generally acquired during childhood, before the 
commencement of sexual activity. Second, it has been pointed out that genital 
schistosomiasis may increase the risk of HIV infection through its disruption of 
the genital tract epithelium.8 Third, schistosomiasis can stimulate a Th-2-type 
immune response similar to other chronic parasitic infections. This produces 
changes in cytokines and an accompanying upregulation of the HIV coreceptors 
CC chemokine receptor 5 and CXC chemokine receptor 4 on monocytes and 
lymphocytes, with an overall shift in the body’s immune response away from the 
Th-1 immunity that provides early initial control in HIV infection.16,17 Fourth, the 
inflammatory reaction to schistosomal eggs in genital lesions may increase the 
numbers of lymphocytes and activated macrophages in the cervical tissue; these 
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are target cells for HIV infection. Finally, HIV-positive patients with helminth 
co-infections appear to have higher viral loads than those without co-infections, 
and thereby may experience both higher rates of HIV transmission and more 
rapid HIV progression.17,18 For all of these reasons, the WHO and others have 
suggested that mass treatment of FUS may be an effective strategy for decreasing 
HIV transmission in sexually-active women in Africa.1,9
The association of FUS with younger age of 18 to 29 years is consistent with the 
natural history of schistosomiasis and has important public health ramifications. 
The age of peak prevalence for Schistosoma haematobium infection is between 
8 and 15 years old, with peaks in the later end of this spectrum occurring in 
communities with lower prevalence of disease.19--21 Repeated exposure to the 
parasite over time leads to the development of at least partial immunity in 
later adulthood.19,21 Our findings demonstrate that, in communities in which 
the prevalence of disease is at least moderate in children [50-90% in a previous 
study],10 women continue to have urogenital schistosomiasis throughout their 
teens and twenties. This is also the age at highest risk for HIV transmission.22 
Women between the ages of 18 and 29 are not a focus of school-based anti-
schistosomal treatment campaigns in sub-Saharan Africa, but the substantial 
burden of FUS in this age group argues strongly for targeted FUS treatment.
Our study suggests that, while S. mansoni may be geographically isolated near 
the Lake shores, S. haematobium may be more widespread in inland villages 
throughout the region, placing more women at risk for urogenital schistosomiasis 
and, potentially, increased HIV transmission. A school-based survey in central 
Sudan reported a comparable marked variation in the prevalence and intensity 
of both infections, even over short distances within the same province.23 A 
compilation of over 2000 studies conducted in East Africa between 1980 and 
2009 revealed starkly distinct distributions for S. mansoni and haematobium, 
including the observations that S. mansoni is most prevalent along the shores of 
large lakes including Lake Victoria.24 Near Lake Victoria in Tanzania, studies in 
schoolchildren have similarly found that the prevalence of S. mansoni decreased 
and that of S. haematobium increased with increasing distance from the lake.10,25 
Thus although our designation of “Northern” and “Southern” villages was not 
chosen a priori, our finding of significantly distinct parasite distributions in each 
of these regions is supported by other studies in the region.
This clustering has been attributed to differences in the ecology preferred by the 
intermediate snail vectors Biomphalaria spp. (for S. mansoni) and Bulinus spp. 
(for S. haematobium). Bulinus snails are capable of aestivation, and are thus able 
to colonize and survive in temporary water sources that dry up for months of 
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the year. In contrast, Biomphalaria snails do not aestivate and therefore require 
large permanent bodies of water with at least moderate aquatic vegetation for 
survival.26 Because of these characteristics, transmission of S. haematobium is 
generally more widespread than S. mansoni but is also more seasonal, with highest 
transmission occurring after the rainy season when snails are not dormant.25,26 
Another important finding from this study was the high prevalence of depression 
among these women in rural villages. We found that 20% of women scored 10 or 
above on the PHQ-9 scale, consistent with moderate to severe depression. A PHQ-9 
score above 10 is 88% sensitive and 88% specific for major depression as defined 
by the DSM-IV criteria.15 Other community-based studies in sub-Saharan Africa 
have reported a similar, though slightly lower, prevalence of major depression 
by DSM-IV criteria in 5--15% among women, with a higher prevalence in those 
living in rural settings.27,28 Thus our findings highlight an additional prevalent 
healthcare need that affects rural women in sub-Saharan Africa.
This work underscores the significant burden and breadth of diseases—including 
parasitic, sexually-transmitted, and mental health-related—in women of 
reproductive age living in rural northwest Tanzania. Due to resource constraints, 
we relied on single urine and stool samples to estimate prevalence of intestinal 
and urogenital schistosomiasis. In all likelihood, had we analyzed urine and 
stool samples on three consecutive days, the prevalence of these infections would 
have been even higher than those we observed. Schistosomiasis in women of 
reproductive age is not currently a focus of public health screening or treatment 
but the infection is common and widespread among this population. It has been 
pointed out that control of FUS, and possibly the opportunity to curtail new HIV 
infections, may cost as little as 32 cents per woman.9
In conclusion, female urogenital schistosomiasis is a geographically-clustered 
infection that disproportionately affects women younger than 30 years of age and 
was significantly associated with HIV infection. These young women, who also 
have the highest risk for incident HIV infection and in whom genital lesions may 
be reversible if treated early, should be the focus of public-health interventions 
aimed to reduce further the prevalence of Schistosoma haematobium infection.
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Abstract
Animal and human studies suggest that Schistosoma mansoni infection may 
increase risk of human immunodeficiency virus (HIV) acquisition. Therefore, 
we tested 345 reproductive age women in rural Tanzanian villages near Lake 
Victoria, where S. mansoni is hyperendemic, for sexually transmitted infections 
(STIs) and schistosomiasis by circulating anodic antigen (CAA) serum assay. Over 
one-half (54%) had an active schistosome infection; 6% were HIV-seropositive. 
By univariate analysis, only schistosome infection predicted HIV infection (odds 
ratio [OR] = 3.9, 95% confidence interval = [1.3–12.0], p = 0.015) and remained 
significant using multivariate analysis to control for age, STIs, and distance from 
the lake (OR = 6.2 [1.7–22.9], p = 0.006). HIV prevalence was higher among 
women with more intense schistosome infections (p = 0.005), and the median 
schistosome intensity was higher in HIV-infected than –uninfected women (400 
versus 15 pg CAA/mL, p = 0.01). This finding suggests that S. mansoni infection 
may be a modifiable HIV risk factor that places millions of people worldwide at 
increased risk of HIV acquisition.
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Introduction
Schistosomiasis is caused by a parasitic infection that affects over 200 million 
people worldwide, with approximately 85% of cases in Africa (1,2) Previously, 
in a cross-sectional study of Tanzanian women, we found that the odds of being 
infected with human immunodeficiency virus (HIV) were fourfold higher 
for subjects with Schistosoma haematobium infection than subjects without S. 
haematobium (3), and we postulated that the chronic genital inflammation caused 
by S. haematobium eggs pre-disposes to HIV infection. We observed a similar 
trend in women with S. mansoni infection, although the numbers were small, and 
the association did not reach statistical significance (unpublished data). 
Primate models support the hypothesis that S. mansoni infection predisposes to 
HIV infection. Rhesus macaques with active S. mansoni infection were 17 times 
more susceptible to simian HIV (SHIV) acquisition after rectal inoculation than 
macaques without S. mansoni (4). Although a variety of interactions between 
S. mansoni and HIV infection in humans have been described (5–10), a direct 
association between active S.mansoni and HIV has not been documented in 
humans. If S. mansoni is a risk factor for HIV acquisition, this finding could 
have major implications for HIV prevention work in much of the world. We, 
therefore, performed a cross-sectional study to explore the relationship between 
S. mansoni and HIV infections in women living on the shores of Lake Victoria, 
including screening for other genital tract infections, which are well-known HIV 
risk factors, to adjust our analysis for any possible confounders.
The screening of large numbers of women in S. mansoni-endemic villages was 
facilitated by the use of a sensitive and specific serum test for the diagnosis of 
Schistosoma infection. The circulating anodic antigen (CAA) test detects a 
Schistosoma worm antigen in the serum, and it is 80–95% sensitive and 98–100% 
specific for diagnosis of schistosomiasis (11–13). CAA is a highly glycosylated 
excretory antigen originating from the parasite gut and released into the host blood 
circulation when the worm regurgitates the undigested compounds of the gut (14). 
Schistosome circulating antigen detection performs well in both HIV-negative and 
-positive individuals (9), and it is recognized by the World Health Organization as 
an alternative diagnostic method to parasitologic examination of multiple stool or 
urine samples (15,16).
Materials and methods
Study sites and subjects. This study was conducted in seven rural villages with 
high rates of both S. mansoni and HIV, chosen for their locations at a distance 
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of 1–25 km from Lake Victoria in western Tanzania (Figure 1). Lake Victoria is 
infested with the Biomphalaria snail, the intermediate host of S. mansoni, and 
inhabitants of the study sites have among the highest prevalence of S. mansoni 
infection in the world.
Repeat surveys conducted by our group between 1999 and 2011 have documented 
a high prevalence of S. mansoni in these villages; in contrast, the prevalence of 
S. haematobium is < 3% in 
adults in the same villages 
(3,17–20)95% confidence in-
terval [CI] = 1.2-13.5. HIV 
is also prevalent in these vil-
lages; a 2004 study showed 
that 8% of adults greater than 
15 years of age were HIV-in-
fected (21). The major mode 
of HIV transmission is het-
erosexual intercourse, and 
there are more females than 
males infected, with a female 
to male ratio of HIV infec-
tion of 1.2:1.0 (21).
We recruited women ages 
18–50 years who were 
seeking routine pre-natal, 
post-natal, or pediatric care 
for themselves or their newborn children in the seven study villages. The study 
team visited each of the health posts for 1 week between January of 2010 and 
August of 2011 and invited consecutive women at the posts to participate in the 
study.
Study procedures and sample collection. The study included an oral question-
naire, a gynecologic exam, and phlebotomy. Gynecologic examinations included 
wet preparations, which were examined on-site for diagnoses of Trichomonas 
vaginalis, Candida species, and bacterial vaginosis by the criteria in the work 
by Amsel and others (22). Endocervical swabs were collected for Chlamydia 
trachomatis and Neisseria gonorrhoeae testing at the laboratory of the National 
Institute for Medical Research (NIMR) in Mwanza, Tanzania. Venous blood 
was also collected, and serum was separated and stored at –20°C at the NIMR 
laboratory. Testing for syphilis and preparation of a portion of CAA test strips 
Figure 1. Lake Victoria, Surrounding Countries, 
and the Study Area. 
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were performed at NIMR. Additional test strip preparation and all test strip 
reading were performed at the Leiden University Medical Center.
Women were offered on-site voluntary HIV counseling and testing in Kiswahili 
by a trained nurse counselor. Rapid tests (SD Bioline; Standard Diagnostics, Inc., 
Kyonggi-do, South Korea) were used with confirmatory testing by a second test 
(Alere Determine; Inverness Medical, Princeton, NJ) as per the national testing 
algorithm, and patients received their results and post-test counseling on the 
same day.
Patients diagnosed with HIV were referred to the local HIV clinic for free care and 
treatment. Women with trichomoniasis, candidiasis, or bacterial vaginosis were 
provided treatment on the same day. Women who tested positive for gonorrhea, 
chlamydia, syphilis, or schistosomiasis were treated at a followup visit as soon as 
laboratory results were available.
Laboratory analyses. Schistosoma. CAA is a glycoprotein that is produced by gut 
epithelial cells of schistosomal worms (14) and secreted in large quantities into the 
host bloodstream during active infection (23). The CAA test does not distinguish 
S. haematobium from S. mansoni infection. The test usually becomes negative 
within 1 week of successful antischistosomal therapy (24). CAA testing was 
performed using the upconverting phosphor (UCP) technology lateral flow assay 
as previously described (12). Serum was treated with 4% (wt/vol) trichloroacetic 
acid to remove proteins and antibody complexes.
After centrifugation, the supernatant was mixed with an assay buffer containing 
an anti-CAA mouse monoclonal antibody conjugated to UCP reporter particles 
and incubated for 1 hour at 37°C. The mixture was applied to a lateral flow test 
strip with a capture line of the same antibody, and chromatography was permitted 
to continue until strips were dry. Strips were read using a modified Packard 
Fluorocount meter, and test line results were normalized to the control line results 
for each test strip. A CAA value ≥ 10 pg/mL was considered positive based on a 
series of negative controls (highest value plus 2 SDs). CAA values were stratified 
by intensity as greater or less than 3,000 pg/mL, which represents approximately 
100 eggs per 1 gram of stool (25).
C. trachomatis and N. gonorrhoeae. DNA was extracted from endocervical swab 
specimens and tested for C. trachomatis and N. gonorrhoeae using Amplicor CT/
NG specimen preparation, amplification, internal control, and detection kits 
(Roche Molecular Systems, Branchburg, NJ). Gonorrhea results were confirmed 
using 16S rRNA PCR testing.
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Syphilis serology. Serum was tested for syphilis using the Rapid Plasma Reagin 
(RPR) test, with confirmation of positive RPR results by the Treponema pallidum 
Particle Agglutination assay (TPPA).
Ethics. The study was approved by the Institutional Review Boards at Bugando 
Medical Center and Weill Cornell Medical College and the National Institute 
for Medical Research in Tanzania. All women were informed about the study 
by a nurse fluent in Kiswahili and provided written informed consent before 
participation.
Statistical methods. Data were entered into a REDCap database (Vanderbilt 
University, Nashville, TN) and analyzed using Stata version 11 (Stata Corporation, 
College Station, TX). Continuous variables were summarized by median and 
interquartile range (IQR), and categorical variables were summarized by 
frequency and percentage. Simple logistic regression (for univariate analysis) 
followed by multiple logistic regression (for multivariate analysis) were used to 
examine factors associated with HIV. In multiple logistic regression models, 
comprehensive adjustment was not pursued, because it yielded failure in 
convergence. Associations between factors and the endpoint were summarized 
using odds ratios (ORs) with 95% confidence intervals (CIs) and associated P 
values. In regression analyses, age and distance from the lake were analyzed as 
continuous variables, whereas other variables were analyzed as binary variables.
We also compared the intensity of schistosome infection between the HIV-
positive and -negative groups using the non-parametricWilcoxon test (because of 
severe non-normality of this data) and the non-parametric Jonckheere–Terpstra 
(JT) trend test (26). Two-sided hypotheses/tests were assumed for calculation of 
all CIs and P values.
Results
Patient characteristics. We invited 432 eligible women living in seven villages 
within 25 km of Lake Victoria to participate. Of these women, 345 (80%) women 
provided informed consent and completed all study procedures. The median 
age in this population was 30 years (IQR = 24–36) (Table 1). All but one woman 
reported contact with potentially contaminated water at least daily. Over three-
fourths of women had not been treated for schistosomiasis in the past 5 years, and 
more than one-half of women had never been treated.
Prevalence of schistosomiasis, genital tract infections, and HIV. We diagnosed 
active schistosomiasis in 185 (54%) women in this study population (Table 2). 
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Table 1. Baseline Characteristics of 345 Women in Schistosoma mansoni- 
endemic Villages near Lake Victoria in Tanzania.
Characteristic Value
Age in years
     Median 




     Median
     Interquartile range
4 
2-6
Reports more than one sexual partner in past six months 12 (5%)
Reports no current sexual partner 23 (9%)
History of miscarriage 116 (39%)
Distance of village from Lake Victoria
   0-8 kilometers
   9-17 kilometers
   18-25 kilometers
123 (36%)
125 (36%)
  97 (28%)
Daily contact with potentially-infectious water 344 (99%)
Never previously treated for schistosomiasis 178 (52%)
Never previously tested for HIV 114 (42%)
Non-missing data were included in each calculation.









Bacterial vaginosis 19 (6%)
Candidiasis 15 (4%)
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Among those women harboring a schistosome infection, the median CAA value 
was 446 pg/mL (IQR = 86–2,338); 21 of 345 (6%) women were HIV-infected. The 
prevalence of other gynecologic infections ranged from gonorrhea in 1 (< 1%) 
woman to reactive syphilis serology in 26 (8%) women (Table 2).
Factors associated with schistosome infection. In both univariate and 
multivariate analysis, distance from Lake Victoria was the only factor that 
was significantly associated with schistosome infection, with an OR of 0.95 
(0.92–0.97) for each increasing kilometer away from the lake (p < 0.001) 
(Table 3). The highest prevalence was 81% in a village situated < 1 km from the 
shore of Lake Victoria, whereas the lowest prevalence (38–42%) was observed 
in villages that were 12–22 km inland. Age, prior receipt of praziquantel, and 
genital tract infections did not significantly predict whether women were 
currently infected with schistosomes.
Factors associated with HIV infection. Schistosome infection was significantly 
associated with HIV infection, whereas other factors were not. Of 185 women 
with positive CAA levels, 17 (9%) women were HIV-infected, whereas of 160 
women without detectable CAA, 4 (3%) women were HIV-infected (OR = 3.9 












Median age (IQR) 30 (25-36) 29 (23-37) 1.02 [0.99-1.05] 0.15
Received 
praziquantel in past 
5 years
21 (19%) 16 (15%) 1.4 [0.7-2.9] 0.35
Gonorrhea and/or 
chlamydia cervicitis
7 (4%) 9 (6%) 0.7 [0.2-1.8] 0.42
Syphilis 17 (10%) 9 (6%) 1.8 [0.8-4.0] 0.19
Median kilometers 
from Lake Victoria 
(IQR)
10 (1-14) 12 (8-22) 0.95 [0.92-0.97] <0.001
Table 3. Associations of Potential Risk Factors with Schistosome Infection 
(Univariable Analysis).
Non-missing data were included in each calculation.
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were both 2.4, although neither was statistically significant. The OR for 
each increasing 1 year of age was 1.00 (0.95–1.06; p = 0.90). The OR for each 
increasing 1 km away from Lake Victoria, which correlates with living closer to 
major roads, was 1.01 (0.95–1.07; p = 0.71). In multivariate analysis, schistosome 
infection was the single best predictor of HIV infection. Other variables were 
not significant and did not affect the relationship between Schistosoma and HIV 
infection. Specifically, when multiple regression models were used to control 
for age, sexually transmitted infections (STIs), and distance from the lake, the 
association between Schistosoma and HIV remained statistically significant 
with an OR of 6.2 (1.7–22.9; p = 0.006).
The median intensity of schistosome infection was significantly higher among 
HIV-infected than -uninfected women (400 versus 15 pg/mL, p = 0.01). When 
women were stratified by CAA intensity, the prevalence of HIV infection 
significantly increased among groups (p = 0.005 by JT test) (Figure 2).










Median age (IQR) 32 (25-36) 30 (24-36) 1.00 [0.95-1.06] 0.90
Median kilometers from Lake 
Victoria (IQR)
12 (10-22) 10 (8-22) 1.01 [0.95-1.07] 0.71
Chlamydia infection 2 (10%) 13 (4%) 2.4 [0.5-11.4] 0.27
Gonorrhea infection 0 1 (0·3%) --- ---
Positive syphilis serology 3 (16%) 23 (7%) 2.4 [0.6-8.7] 0.19
Trichomonas infection 0 4 (1%) --- ---
Bacterial vaginosis 0 19 (6%) --- ---
Candidal infection 0 15 (5%) --- ---
Positive CAA test 17 (81%) 168 (52%) 3.9 [1.3-12.0] 0.015
Table 4. Associations of Potential Risk Factors with HIV Infection (Univariable 
Analysis*).
*Non-missing data were included in each calculation.
For age and kilometers from the lake, the odds ratio corresponds to the odds ratio 
estimate for one unit increase in the exposure (i.e., per one year increase in age 
and one kilometer increase in distance).
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Factors associated with 
other STIs. Cervicitis cau-
sed by gonorrhea and/or 
chlamydia was significantly 
associated with younger age 
(OR = 0.87 [0.79–0.96] for 
each increasing year of age, 
p = 0.006). No other sig-
nificant associations were 
observed.
Discussion
In women living in S. 
mansoni-endemic areas 
near Lake Victoria, more 
than one-half were schisto-
some-infected, and Schistosoma infection was strongly associated with HIV. 
This finding suggests that S. mansoni infection and the chronic inflammation 
from the gut caused by S. mansoni eggs may be a risk factor for HIV acquisition. 
Schistosomiasis may be placing millions of women throughout sub-Saharan 
Africa at increased risk of becoming HIV-infected, and mass therapy of women 
of reproductive age for schistosomiasis may be an effective HIV prevention 
strategy.
Animal models support the hypothesis that S. mansoni infection increases host 
susceptibility to HIV infection. Studies in macaques showed that the rectal 
inoculum of SHIV required for SHIV acquisition was 17 times lower in macaques 
with than without S. mansoni infection (4). In contrast, prior S. mansoni infection 
did not significantly change the required infectious dose when SHIV was 
inoculated intravenously (4,27). Researchers postulated that S. mansoni infection 
increased the number of activated CD4+ T cells in the gut-associated lymphoid 
tissue (GALT) and thereby increased the optimal targets for SHIV infection. 
Mouse models of schistosomiasis show that S. mansoni eggs induce a Th17 CD4+ 
T-cell response in the gut mucosa (28,29). A growing body of literature suggests 
that HIV preferentially infects Th17 CD4+ T cells in gut and genital tissue 
mucosa and that increased numbers of these cells may increase susceptibility 
to HIV infection (30,31). Additional human studies are needed to determine if 
S. mansoni eggs induce a Th17 cell immune response in the GALT and if these 
Th17 cells express HIV susceptibility factors, such as CC Chemokine Receptor 5 
(CCR5) and integrin α4β7.
Figure 2. Prevalence of HIV Infection by Intensity 
of Schistosome Infection.
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Our work is also supported by recent findings from the Rakai region of Uganda, 
where S. mansoni is endemic (32). As noted perceptively in the work by Secor 
(33), HIV-infected individuals more often had antibodies to schistosome antigens 
than HIV-uninfected individuals. Unlike in our study, in which CAA positivity 
indicates live worm infestation, the detection of antibodies to schistosome 
antigens does not prove active schistosomiasis. Coupled with our findings, this 
population-based study lends additional clinical support to our finding that S. 
mansoni infection and not only S. haematobium infection (as previously reported) 
is associated with HIV.
In addition, S. mansoni-infected individuals displayed higher densities of the HIV 
chemokine receptors CCR5 and CXCR4 on their CD4+ T cells and monocytes 
than individuals with schistosomiasis that had been previously treated (34). S. 
mansoni infection was also shown to increase the HIV RNA viral load in HIV-
positive patients with untreated S. mansoni infection compared with patients 
with S. mansoni infections that had been treated (35). Several earlier non-
randomized studies did not find an effect of praziquantel treatment on viral load 
(5,6,36,37),  but this result has been postulated to be caused by transient increases 
in the schistosomiasis-conducive Th2 environment immediately after treatment 
(5,38). S. mansoni-infected individuals are also reported to excrete fewer ova 
than individuals without HIV (7,10). Our results support these findings that show 
complex interactions between Schistosoma and HIV infections as well as the 
growing consensus that schistosome infection, including S. mansoni, may be a 
risk factor for HIV acquisition (1,33).
Our work suggests that, among rural African women in whom the prevalence of 
genital tract infections is low, schistosome infection may be a major contributor 
of risk for HIV acquisition. Over one-half of our population was infected with 
schistosomes, leading to an estimated population-attributable fraction for HIV 
acquisition caused by schistosome infection of 69% (36–81%) using previously 
described methods (39). In contrast, the population-attributable fractions for 
genital tract infections in our population were 7% and below. The direction of 
our findings supports the well-described association between HIV and STIs, but 
the inability of our study to show statistical significance may be caused by the low 
prevalence of STIs in this rural population. We postulate that, in our population 
and other rural populations with few traditional HIV risk factors, such as 
multiple sexual partners and high rates of genital tract infections, schistosome 
infection may play a role as a key driver of HIV transmission. Of note, this study 
addresses the risk only in women aged 18–50 years who were seen at rural health 
clinics, and it does not address whether men or younger adolescent girls are also 
at increased risk.
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The CAA test is a valuable diagnostic test for schistosome infections. The antigen 
becomes detectable in serum approximately 5 weeks after infection (40). CAA 
levels fall rapidly posttreatment, with a serum half-life of 2 days (24), and they 
rise with reinfection (41). The test is, therefore, highly time-specific for active 
schistosome infections. CAA assays have been recommended for serologic 
screening programs, in which repeated parasitologic examinations of urine and 
stool are logistically complicated (42). The CAA test has recently been developed 
into a very sensitive, robust lateral flow strip test, making test performance in 
rural settings increasingly feasible (12). The test is unable to distinguish between 
species of schistosomal infections. Therefore, projects relying on CAA testing 
either will only allow species-specific conclusions when performed in regions 
with sharp geographic demarcation of schistosome species, like in our study, or 
will not be able to differentiate between schistosome species.
Schistosomiasis is usually acquired in childhood, infecting 50–90% of children 
living in endemic areas by early adolescence (2). Thus, acquisition of schistosome 
worms typically predates sexual activity and concomitant exposure to HIV. The 
World Health Organization recommends that children in endemic areas receive 
targeted, periodic school-based praziquantel treatment (1). Women do not often 
receive mass treatment. In our population, more than one-half of women had 
never received antischistosomal treatment, despite living in a hyperendemic 
area and coming into daily contact with unclean water. A policy of routine 
periodic praziquantel administration for women seeking reproductive 
healthcare services (including family planning, cervical cancer screening, and 
pre-natal/post-natal care) would be a safe (1), efficient, and inexpensive way to 
control schistosomiasis and, moreover, potentially to prevent HIV acquisition 
in this vulnerable group.
This cross-sectional study shows a strong association but does not prove a causal 
role of schistosomiasis in HIV acquisition. An interventional trial would be 
necessary to show causality. However, we feel that the best explanation of our 
findings is that pre-existing schistosome infection modifies mucosal immunity 
and predisposes to HIV infection. The highest incidence of schistosome 
infection typically occurs in childhood between the ages of 5 and 15 years, 
and in individuals with ongoing exposure, it produces a chronic infection 
over decades. More than 80% of our study participants denied receiving 
praziquantel in the past 5 years, and more than one half reported never being 
treated. Therefore, it seems most likely that the large proportion of our study 
participants had chronic, untreated schistosome infection that pre-dated their 
exposure to HIV. Although it is conversely possible that HIV infection increases 
susceptibility to schistosomiasis (43), the former explanation for the association 
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most aptly combines both natural history and biological plausibility data. Also, 
it should be noted that the use of ORs in this study could possibly overestimate 
the relationship between HIV and schistosome infection compared with 
relative risk because of the fact that schistosome infection was common in our 
population (44).
In conclusion, more than one-half of rural Tanzanian women seen at health 
posts in S. mansoni-endemic areas of the Lake Victoria region had evidence of 
active schistosome infection, and the prevalence of HIV among these women was 
markedly higher than among those women without schistosome infection. Active 
S. mansoni infection may be a modifiable HIV risk factor that is contributing to 
high rates of new HIV infections among millions of women living in sub-Saharan 
Africa.
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Abstract
We explored the response to single-dose praziquantel therapy in a cohort of 33 
women with Schistosoma haematobium infection in rural Mwanza, Tanzania. 
Women with S. haematobium infection confirmed both by eggs in urine and 
by polymerase-chain reaction (PCR) received single-dose praziquantel and 
treatment for concomitant sexually-transmitted infections. Macroscopic cervical 
abnormalities were also quantified. After six months, microscopically-detectable 
egg excretion was eliminated but 8 of 33 women (24%) were persistently positive 
for S. haematobium by PCR and 11 (33%) had cervical abnormalities potentially 
attributable to schistosomiasis. This suggests that praziquantel treatment more 
frequently than every six months may be necessary for complete elimination of 
the parasite and prevention of genital tissue pathology. This aggressive therapy 
may in turn play a key role decreasing HIV susceptibility in millions of people 
living in regions in which S. haematobium is endemic.
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Introduction
Schistosoma haematobium is  a parasitic worm infection acquired through 
contact with infested fresh water that affects an estimated 112 million people 
living in sub-Saharan Africa (1). Adult S. haematobium worms live for years in 
host pelvic venous plexi and lay hundreds of   eggs per day (2). The schistosome 
miracidium within the egg secretes proteolytic enzymes through the egg’s shell 
that facilitate the migration of the egg through the vessel wall and into the 
surrounding tissues toward the mucosal tissue and lumen of the genitourinary 
tract (2). Some eggs reach the lumen and are excreted in urine or genital secretions 
(3), but a significant fraction become trapped in the tissues of urogenital organs, 
where they cause acute and chronic inflammation. Histopathological and 
autopsy studies of women with S. haematobium infection demonstrate eggs 
throughout the upper and lower genital tract (4–6). S. haematobium infection 
in women has been associated with HIV infection in cross-sectional studies 
(7–9) and is postulated to increase HIV susceptibility both by damaging the 
mucosal integrity of the female genital tract and by causing local mucosal and 
systemic immune responses (8,10–14).
The World Health Organization (WHO) recommends empiric anti-schistosome 
treatment with praziquantel for at-risk individuals in sub-Saharan Africa to reduce 
disease morbidity and with the possibility of preventing HIV (15,16). In highest-
prevalence areas (>50%), annual single-dose praziquantel is recommended for 
both children and adults (17). Self-report of even one anti-schistosome treatment 
before the age of 20 years in girls has been associated with significantly lower 
rates of genital manifestations of schistosome infection such as sandy patches and 
contact bleeding (18).
Two longitudinal studies have suggested that single-dose praziquantel significantly 
reduces urinary egg excretion but does not completely cure S. haematobium 
infection, particularly its gynecological manifestations. The smaller study 
reported regression of genital sandy patches in 2/4 women re-examined nine 
weeks after treatment but persistence in the other two (19). In the larger study 
of 338 women seen after 12 months, praziquantel treatment was not associated 
with improvements in gynecological abnormalities or contact bleeding (20). In 
order to explore and extend these findings, we added molecular diagnostics to 
investigate response to single-dose praziquantel in a cohort of women with S. 
haematobium infection in rural Tanzania. 
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Methods
Study design. We conducted a six-month cohort study in which women with 
Schistosoma haematobium infection were recruited from the S. haematobium-
endemic villages of Lubiri and Nyamilama, treated with praziquantel, and retested 
after six months. This was a proof-of-concept study to explore the utility of PCR for 
monitoring treatment response in urogenital schistosomiasis. We enrolled women 
only for this preliminary study because our work was incorporated into an ongoing 
women’s health program administered by the Tanzanian Ministry of Health.
As previously-described, women aged 18-50 had been screened for cervical 
cancer using visual inspection with acetic acid (the standard of care in Tanzania) 
in partnership with a governmental outreach program (7). We enrolled women 
who screened negative for cervical cancer and who had S. haematobium infection 
confirmed by visualization of eggs in urine plus were PCR-positive for schistosome 
DNA in urine. We additionally examined cervical smears for eggs and  tested 
cervicovaginal lavages for schistosome DNA. A nurse collected socio-demographic 
data using a structured questionnaire in Kiswahili, the local language. 
Women received free observed treatment with single-dose praziquantel (40mg/
kg) at enrollment. We included pregnant and lactating women as praziquantel 
is recommended for these groups by the WHO (17). Women and their sexual 
partners also received free treatment for the sexually-transmitted infections 
(STIs) for which testing can be routinely done in Tanzania, including syphilis, 
trichomoniasis, chlamydia, gonorrhea, candidiasis, and bacterial vaginosis if 
indicated. Women participated in an educational seminar about schistosomiasis, 
STIs, and possible associations with HIV infection on the day of study enrollment. 
Study participants were re-evaluated for S. haematobium and gynecological 
infections at the six-month follow-up visit and again received indicated treatment 
without cost.
Field investigations. Gynecological examinations were performed at enrollment 
and six months to document any macroscopic cervical abnormalities including 
sandy patches, irregular blood vessels, contact bleeding, condylomata, and 
abnormal discharge. Prior to any sample collection, the cervix was visually 
inspected using a flashlight and magnifying glass. Macroscopic abnormalities 
were identified by the physician and recorded and drawn to scale on a standardized 
data collection form. Abnormal discharge, defined as discharge of any color other 
than white or white discharge that was thick and/or copious, was also noted 
and described on the form. The physician was blinded to the prior examination 
findings at the time of follow-up data collection.
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The first sample collected was a wet preparation  for candidiasis, trichomoniasis, 
and bacterial vaginosis, followed by an endocervical swab for chlamydia and 
gonorrhea as previously described (7,21). Next, cervical smears were taken from 
abnormal-appearing regions if present and otherwise from the transformation 
zone. Lastly, cervicovaginal lavage samples were prepared using four milliliters of 
normal saline to wash the face of the cervix three times. 
Single urine samples at enrollment and follow-up were collected between 10am 
and 2pm, filtered, and examined microscopically for schistosome ova by a trained 
microscopist. Serum was tested by Rapid Plasma Reagin (RPR), with Treponema 
pallidum particle agglutination (TPPA) testing performed on positive samples for 
diagnosis of syphilis.
Real-Time PCR. DNA isolation and PCR was performed as described previously 
(12). Briefly, DNA was isolated from well-mixed pre- and post-treatment urine 
and cervicovaginal lavages using QIAamp Tissue Kit spin columns (QIAgen, 
Hilden, Germany). Quantitative real-time PCR testing was performed using 
Schistosoma genus-specific primers and detection probe. PhocineHerpes Virus 
1 (PhHV-1) was used as an internal control in each sample along with PhHV-
1-specific primers and detection probe to detect any inhibition. Amplification, 
detection, and analysis were performed with the CFX96 real-time detection 
system (Bio-Rad laboratories). The PCR output from this system consists of 
a cycle-threshold (Ct) value, representing the amplification cycle in which the 
level of fluorescent signal exceeds the background fluorescence, and reflecting the 
parasite-specific DNA load in the sample tested. Negative and positive control 
samples are included in each amplification run.
Statistics. Continuous variables were summarized by median and interquartile 
range (IQR) and categorical variables were summarized by frequency and 
percentage. Proportions were compared using Fisher’s Exact test and continuous 
variables by the Wilcoxon rank-sum test. Pre-post treatment values were compared 
with the Wilcoxon matched-pairs signed-rank test. Two-sided hypotheses/tests 
were assumed for all confidence intervals and p-values. Data were analyzed using 
Stata Version 11 (College Station, Texas).
Ethics. Written informed consent was obtained by a trained study nurse fluent in 
the local language who read the consent form to all study participants. Women 
who decided to participate signed their names or made their mark/thumbprint 
(if illiterate) on the consent form. Ethical permission was granted by Bugando 
Medical Centre, the Tanzanian National Institute for Medical Research, and 
Weill Cornell Medical College. 
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Results
Patient characteristics. Between November 2009 and May 2010, we enrolled 39 
women with S. haematobium infection detected by both microscopy and PCR. 
Of these, 33 (85%) were re-examined a median of 188 (IQR, 183-188) days after 
treatment and included in the analysis. There were no significant differences 
between age or number of urinary ova between women who were lost to follow-up 
(n=6) and those who were not.
 Socio-demographic information is detailed in Table 1. Patients were young, with a 
median age of 22 (20-28) years, and 6 patients were aged 18-19. The large majority 
(90%) were married. Sexual risk factors were assessed indirectly. Nearly one-third 
of women had children with at least two different men, and more than half of 
women stated that their husbands had children with another woman during the 
marriage. Ten women (30%) reported going to bed hungry in the past month 
Table 1. Demographic Characteristics of 33 Adult Women  (>18 years) Treated 
for Urogenital Schistosomaisis and Followed Up After Six Months.
CHARACTERISTIC VALUE
Age in years—median (interquartile range) 22 (20—28)
Married—number (percent) 28 (90%)
Number of children
   0
   1--2 
   3--4





Number of fathers of a woman’s children
   1
   2




Husband had children outside of marriage during the 
marriage—number (percent)
18 (55%)
Went to bed hungry in past month—number (percent) 10 (30%)
Reported no prior treatment for schistosomiasis—number 
(percent)
8 (24%)
Non-missing data were included for each calculation.
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because their household did not have enough food, a measure of food insecurity 
(22,23).
Microscopy and PCR pre- and post-treatment. At enrollment, all women 
had urinary ova with a median of 8 (4-53) per 10 milliliters. Three women 
additionally had viable S. haematobium ova in cervical smears. All 33 women 
had positive urine PCR results. Urine Ct values ranged from 20.6-36.3 (median 
27.8). Cervicovaginal lavage PCRs were positive in 9 women (27%), ranging from 
19.9-35.1 (median 28.3). Two of the three women with eggs in cervical smears had 
PCR-positive lavages.
Six months after treatment, ova were no longer detected in any urine or 
cervical sample. Eight women (24%) still had detectable schistosome DNA by 
PCR with Ct values <35 (six urines and two lavages, Figure 1). In women with 
persistently positive PCR findings, the DNA quantity remained approximately 
unchanged. Urine PCRs became zero in the two women with persistently-
positive lavages.
Gynecological abnormalities pre- and post-treatment. STIs diagnosed included: 
four chlamydia (12%) and one each (3%) of syphilis, gonorrhea, trichomoniasis, 
and multiple cervical condylomata. At enrollment, 9/33 women (27%) were 
negative for STIs but had at least one macroscopic gynecological abnormality 
Figure 1. Pre- and Post-Treatment Urine Egg, Urine Schistosome PCR, and Cervico-vaginal Lavage 
Schistosome PCR.
Results for each patient are shown at the time of praziquantel treatment (Month 0) and follow-up 
examination six months later (Month 6). PCR, Real-Time Polymerase Chain Reaction to detect 
schistosome DNA. Bold red line indicates the mean value of all women tested (n=33).
 Urinary Egg Excretion Urine Schistosomal PCR Lavage Schistosomal PCR
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that, in the absence of STIs or malignancy, could be consistent with Schistosoma 
involvement of the genital tract (Table 2). These included sandy patches, contact 
bleeding, convoluted blood vessels, and abnormal discharge. 
After treatment, the same macroscopic abnormalities persisted in 7 of these 9 
women, and four others had new abnormalities that could be consistent with 
cervical Schistosoma infection in the absence of STIs and malignancy. Thus we 
observed, in total, 11 women (33%) with gynecological abnormalities that were 
possibly consistent with schistosomiasis six months after praziquantel treatment. 
Four of these 11 (36%) were persistently PCR-positive (3 urines and one lavage), 
compared with 4 (18%) of the 22 who had no gynecological abnormalities 
(p=0.25). Ages were not significantly different between groups of women who 
remained positive by PCR or who had persistent gynecological abnormalities and 
those who did not.
In total, 10 women had evidence of S. haematobium involvement of the genital 
tract by eggs or PCR at the time of enrollment, and 6 months after treatment, 
2 (20%) remained PCR-positive in cervicovaginal lavages. Schistosome DNA 
additionally was detectable in urine of 6 other women at 6 months. Of the 25 
women who were negative for both schistosome eggs and DNA at 6 months, 7 
(28%) had gynecological abnormalities in the absence of STIs or cervical cancer, 
suggestive of S. haematobium-induced pathology. 
Discussion
In this cohort of 33 young adult women with Schistosoma haematobium infection 
who received single-dose praziquantel therapy, Schistosoma DNA was detectable 
6 months later in the genital tract of 2/10 women with initial genital tract 
involvement and in urine of 6 additional women.  Moreover, nearly one-third 
had ongoing cervical pathology potentially attributable to schistosome infection. 
Our findings suggest that, after single-dose praziquantel, which is the WHO’s 
current recommendation for schistosomiasis (24), parasite remnants and genital 
tract tissue pathology persist in a substantial minority of adult women. Other 
groups have advocated higher and/or repeated praziquantel doses (25–27). Our 
work supports this concept and raises serious concern given recent findings that 
schistosomiasis may be a risk factor for HIV acquisition (7,8,21).
Schistosoma real-time PCR has been evaluated as an indicator of genital S. 
haematobium infection (28) but not as a marker of effectiveness of praziquantel 
treatment. Our work documents that Schistosoma DNA was detectable six months 
after treatment in 8/33 women whose negative egg counts appeared to indicate 
Chapter 4  71
Table 2. Findings in 33 Adult Women (>18 years) Treated for Schistosoma 
haematobium Infection and Re-tested after Six Months. 
Measurement Pre-Treatment Six Months 
Post-Treatment
p-value
Urine PCR (Ct value)
   Positive urine PCR—    
        number (percent)
   Median
   Interquartile range (IQR)











Urinary ova (per 10 ml)
   Positive urinary ova— 
        number (percent)
   Median
   IQR











Lavage PCR (Ct value)
   Positive lavage PCR— 
         number (percent)
   Median
   IQR











Positive cervical smear ova—
number (percent)
3 (9%) 0 n.s.
Convoluted blood vessels—
number (percent)
1 (3%) 2 (6%) n.s.
Sandy patches—number 
(percent)
7 (21%) 9 (27%) n.s.
Contact bleeding—number 
(percent)
1 (3%) 1 (3%) n.s.
Abnormal discharge—number 
(percent)
2 (6%) 1 (3%) n.s.
Any gynecological 
abnormality potentially 
consistent with genital S. 
haematobium infection—
number (percent)
9 (27%) 11 (33%) n.s.
n.s. = not significant
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resolved infection. Previous studies in Zimbabwe and Malawi have similarly 
reported unresolved macroscopic gynecological pathology (sandy patches, blood 
vessel abnormalities, and/or contact bleeding) in women treated for genital 
S. haematobium infection and any STIs and re-examined up to a year later 
(19,20). Our work now substantiates these clinical reports by showing that, after 
praziquantel treatment, a sizeable percentage of women have not only ongoing 
cervical pathology but also detectable parasite DNA in urine and cervicovaginal 
lavage fluid.
The persistence of gynecological lesions potentially caused by S. haematobium 
suggests that S. haematobium-induced pathology may be irreversible. Liver 
fibrosis due to S. mansoni infection is often permanent even after parasite death 
(29). Similarly, gynecological lesions are believed to begin as inflammatory tissue 
reactions to migrating ova (30,31) which, over time, become fibrotic “sandy patches” 
(18,30) that may not be curable. In support of this hypothesis, women from an S. 
haematobium-endemic region who reported receiving praziquantel before age 20 
were less likely to have gynecological contact bleeding and sandy patches than women 
treated after age 20 (18). Thus regulartreatment beginning in childhood appears 
optimal to prevent potentially-irreversible genital lesions that may predispose to 
HIV infection (11,16,18). Establishment of the most effective treatments for genital 
S. haematobium infection remains an urgent research priority. 
A limitation of this study was our inability to determine whether Schistosoma DNA 
detected at six months was due to re-infection, sample contamination by semen 
of infected sexual partners or by stool, partial treatment failure, post-treatment 
maturation of juvenile worms which are less susceptible to praziquantel (32), or 
lingering ova and parasite products in tissue and blood (33). We believe that the 
latter three explanations are the most likely sources of DNA in urine samples, 
which were clean-catch and showed no ova. Cervicovaginal lavages are inherently 
not sterile and could more easily have been contaminated. Second, neither testing 
for Herpes simplex virus and Human papillomavirus infections, nor exclusion of 
premalignant lesions, was possible. Lastly, the sensitivities of cervical smears (34), 
PCR of cervicovaginal lavages (particularly in women older than age 25) (28), 
and single rather than double urine samples are all suboptimal for detection of S. 
haematobium infection. Lower sensitivity would bias our study towards finding 
less residual infection in patients with confirmed S. haematobium at the study 
outset. Thus our detection of persistent schistosome DNA in 8/33 women may 
be low. Either way, our findings suggest that treatment may need to be repeated 
more frequently than the WHO recommends (annually) and more frequently 
than even the six-month duration of this study in order to maximize parasite 
elimination and minimize tissue pathology.
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In conclusion, our results suggest that single-dose praziquantel does not 
completely eliminate S. haematobium DNA in a substantial portion of women. 
Moreover, one dose of praziquantel appears not to reverse cervical pathology. 
Our data supports using praziquantel early and often in girls and women living 
in endemic areas. Given that S. haematobium may be a risk factor for HIV 
acquisition, this low-cost ($0.32) (11) intervention may have the potential not only 
to lessen schistosome-related morbidity, but also to prevent new HIV infections 
among millions of at-risk women in Africa.
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Abstract
Circulating Anodic Antigen (CAA) testing is a powerful, increasingly-used 
tool for diagnosis of active schistosome infection. We sought to determine the 
feasibility and reliability of measuring CAA in blood spots collected on Whatman 
903 Protein Saver cards, which are the predominant filter papers used worldwide 
for dried blood spot (DBS) research and clinical care.
CAA was eluted from blood spots collected from 19 individuals onto Whatman 
903 cards in Mwanza, Tanzania, and the assay was optimized to achieve CAA 
ratios comparable to those obtained from the spots’ corresponding serum 
samples. The optimized assay was then used to determine the correlation of 
serum samples (n=16) with DBS from cards that had been stored for 8 years at 
ambient temperature. Using a DBS volume equivalent to approximately four 
times the quantity of serum, CAA testing in DBS had a sensitivity of 76% and a 
specificity of 79% compared to CAA testing in serum. CAA testing was reliable 
in samples eluted from Whatman 903 cards that had been stored for 8 years at 
ambient temperature. The overall kappa coefficient was 0.53 (standard error 0.17, 
p<0.001).
We conclude that CAA can be reliably and accurately measured in DBS collected 
onto the filter paper that is most commonly used for clinical care and research, 
and that can be stored from prolonged periods of time. This finding opens new 
avenues for future work among more than 700 million individuals living in areas 
worldwide in which schistosomes are endemic.
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1. Introduction
The schistosome Circulating Anodic Antigen (CAA) assay is a test of high 
importance for both the estimated 260 million individuals worldwide with 
schistosome infection, as well as the 700 million who live in endemic areas and 
are at risk of schistosome acquisition (1,2). CAA is a glycoprotein produced 
in the gut of schistosome worms (3) that is secreted into the host bloodstream 
during active schistosome infection. CAA correlates closely with infection status, 
making the test useful not only for diagnosis but also for monitoring treatment 
response (4–7). 
Compared to the traditional diagnosis of schistosomiasis by microscopic 
examination for eggs in multiple urine and stool samples, schistosome antigen 
testing offers advantages of single sample collection, elimination of labor-
intensive work with excrement, and enhanced sensitivity with the potential to 
detect as little as one worm pair (8). Antigen testing has also been recommended 
for serologic screening programs in which repeated examinations of urine and 
stool are logistically not possible (9) and for diagnosis of young children, from 
whom obtaining urine and stool samples is difficult (10). Given that the CAA 
assay has recently been developed into a dry-reagent lateral flow assay with 
a portable reader that can be easily transported to, and operated in, resource-
limited settings (11), its utilization will likely continue to increase.
From a laboratory standpoint, the CAA assay is an appealing test. The antigen’s 
unique carbohydrate structure has no known biological equivalent (11,12), and 
recent modifications make the assay highly sensitive (13). CAA is heat-resistant 
and extremely stable, remaining detectable in tissue isolated from Egyptian 
mummies (14). While this would suggest that CAA might be easily measured 
in dried blood spot (DBS) samples, two early studies that explored this issue in 
several types of filter paper have shown that CAA was detectable but that available 
concentrations were low (15,16). Of note, these studies did not evaluate Whatman 
903 Protein Saver cards, which cost approximately USD $1.50 each and are the 
most commonly-used filter papers for HIV testing and monitoring worldwide, 
including early infant HIV diagnosis and HIV drug resistance genotyping (17,18). 
Whatman 903 cards have additionally been validated for detection of malaria 
gametocyte RNA by qRT-PCR (19,20). Given that numerous projects currently 
collect DBS from regions in which schistosomiasis, HIV, and malaria are co-
endemic and that the ability to test these DBS for schistosomiasis would be useful 
for future patient care and research, we sought to determine the feasibility and 
reliability of measuring CAA in DBS on Whatman 903 cards, as compared to 
serum, from patients in Tanzania where all three infections are co-endemic.
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2. Materials and Methods
2.1 Study site. Samples for this study were collected in the Kisesa ward in 
northwest Tanzania, located approximately 20 kilometers east of Mwanza city. 
We have previously demonstrated that the prevalence of schistosomiasis by CAA 
in serum is ~50% among adult women in this region near Lake Victoria (21), with 
a similar prevalence in adult men (unpublished data). Urine and stool microscopy 
demonstrated that the predominant species in the region is S. mansoni, with 
approximately 25% of community-based participants in prior studies having S. 
mansoni ova visualized in stool and approximately 2-3% having S. haematobium 
ova visualized in urine.
2.2 Sample collection for assay optimization. In April 2012, we invited women 
of childbearing age who were seeking care for themselves or their children at 
the Kisesa Health Centre to participate in this study.  Four milliliters of blood 
were collected by venipuncture from the antecubital fossa and five spots of blood 
(each ~13 millimeters in diameter) were collected by fingerstick lancet onto 
Whatman 903 Protein Saver cards (GE Healthcare Life Sciences, Piscataway, NJ, 
USA). Cards were dried away from direct sunlight, placed into individual zip 
bags 24 hours after collection, and stored at room temperature until processing. 
Venous blood was centrifuged upon return to the National Institute for Medical 
Research Laboratory in Mwanza City approximately 20 kilometers away, and 
serum was stored at -20C. All women were given empiric praziquantel (40mg/kg) 
in accordance with World Health Organization guidelines (22).
2.2 Dried blood spot sample preparation. To elute dried samples from cards, we 
cut sections from the DBS and placed them into eppendorfs containing 100µL 
of phosphate-buffered saline. The sections were incubated overnight at 4C, then 
placed on a shaker for 1 hour at 37C, after which 100µL of 4% (w/v) tricholoroacetic 
acid (TCA) was added and the mixture vortexed and centrifuged. We first eluted 
a 24mm2 DBS into a total volume of 200µL. In order to increase the sensitivity, we 
subsequently eluted DBS with a total area of 144mm2 into final concentration of 
2% TCA. The supernatant from these elutions was concentrated to a final volume 
of 20-30µL using a 10kDa concentration device (Amicon Ultra-0.5ml Centrifugal 
Filters, Millipore Corp). 
2.3 CAA test strip preparation and testing. Serum samples (20µL) were mixed 
with an equal volume of 4% TCA, vortexed, and centrifuged. Twenty microliters 
of this supernatant, 20µL of the supernatant of the eluted samples from the small 
circles, or all of the concentrated eluate supernatants were subsequently mixed 
with assay buffer containing UCP reporter particles labelled with anti-CAA 
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McAb, incubated, and applied to CAA-specific lateral flow test strips as previously 
described (8,11,23). Strips from serum samples were prepared at the local 
laboratory in Mwanza, Tanzania and then shipped with DBS to Leiden University 
Medical Centre for subsequent testing. Elutions, CAA strip preparation for eluted 
samples, and CAA strip scanning using a modified Packard Fluorocount meter 
were performed at Leiden University Medical Centre. The test line signal was 
normalized to the control line signal for each individual sample. Standards of 
known concentrations, run with each assay, were used to construct a standard 
curve and to determine the cut-off point above which samples were considered 
positive, which corresponded with 30pg/ml.
2.4 Additional testing in banked dried blood spots. Following optimization of 
the assay, we obtained additional paired serum and DBS samples from the same 
Kisesa region that had been collected onto the same Whatman 903 cards from 
adults aged 15-49 years in 2005. The cards had been stored with desiccant packs 
in separate zip bags at room temperature. CAA strips from serum samples were 
prepared in Mwanza; DBS elution and subsequent processing were performed in 
the Netherlands. Elutions were performed using 216mm2 of dried sample and 600 
µl PBS as described above, with the subsequent addition of 138 µl of 12% TCA 
(resulting in a final 2% (w/v)). The total volume of supernatant was concentrated 
to 20-30 µl.  
2.5 Statistical analysis. Results were entered into Microsoft Excel and analyzed 
using Stata/IC Version 13 (College Station, TX, USA). Correlation between log-
transformed CAA concentrations was determined using Pearson’s correlation 
coefficient. Agreement between positive and negative test results was assessed 
using Cohen’s kappa coefficient.
2.6 Ethics. This project was approved by the joint Bugando Medical Centre/
CUHAS Research and Publications Committee, the National Institute for Medical 
Research in Tanzania, and Weill Cornell Medical College. Study participants 
provided informed consent for their participation.
3. Results
3.1 Available samples. Paired serum and DBS were available from a total of 35 
individuals. Nineteen participants provided fresh blood and DBS in April 2012, 
which were used for test optimization between April and July 2012. The other 16 
patients had both serum and DBScollected and banked in 2005; these samples 
were tested in March 2013. If serum results from 2005 diverged strongly from 
DBS results both samples were retested in August 2013.
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3.2 Optimization of dried blood spot testing. By serum testing, 11 of the 
19 samples (58%) collected for optimization were positive for CAA, with 
concentrations greater than 
10 pg CAA/ml. Testing of 
DBS was initially performed 
using small 24mm2 DBS. 
This yielded positive results 
only in four of the samples 
that had been most strongly 
CAA-positive on serum 
testing (CAA >200pg/ml). 
When the DBS area was 
subsequently increased to 
144mm2 (corresponding to 
approximately 30µL of dried 
serum), 8 of 11 spots were 
positive (Figure 1). Among 
the 8 serum-negative 
samples, one was positive 
for CAA on DBS (50pg/ml, 
versus 1pg/ml in serum). 
The remaining seven were 
negative for CAA both in serum and DBS. 
CAA values from serum and from 144mm2 DBS samples were plotted against 
each other. Red solid vertical and horizontal lines indicate the cut-off value of 
10pg/ml, above which a patient is considered “CAA-positive.” The diagonal line 
indicates perfect 1:1 correlation. The majority of samples’ plotted values fall 
below the diagonal line, indicating higher concentrations obtained from serum 
than from DBS.
3.3 Application of optimized assay to banked dried blood spots. By serum 
testing, 10/16 patients (63%) who had serum collected eight years previously 
were CAA-positive. Their corresponding DBS, which had been stored at 
room temperature for eight years, were positive in 9 of these 10 patients. 
Figure 2 demonstrates the linear correlation between serum and DBS CAA 
concentrations, with a Pearson’s correlation coefficient of 0.70 (p<0.001). The 
three samples that appear most divergent were re-tested blindly and again had 
similarly divergent values. As seen in the samples used for optimization, CAA 
concentrations measured in serum appear to be slightly higher than those 
obtained from the DBS. 
Figure 1. Serum CAA versus optimized dried blood spot 
values (n=19).
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CAA values from eight-year-
old serum and from DBS 
samples were plotted against 
each other. Red solid vertical 
and horizontal lines indicate 
the cut-off value of 10pg/
ml, above which a patient is 
considered “CAA-positive.” 
The diagonal line indicates 
perfect 1:1 correlation. The 
majority of samples’ plotted 
values fall below the diagonal 
line, indicating higher 
concentrations obtained 
from serum than from blood 
spots. DBS testing correctly 
identified as CAA-positive 
9 of 10 samples that were 
CAA-positive in serum.
3.4 Overall performance measures. Considering all 35 samples tested with 
serum as the “gold standard,” the overall sensitivity and specificity of DBS testing 
were 76% (16/21) and 79% (11/14), respectively. The overall kappa coefficient was 
0.53 (standard error=0.17, p<0.001).
4. Discussion
Our work demonstrates that schistosome CAA can be reliably and accurately 
quantitated in DBS stored on Whatman 903 Protein Saver cards, yielding 
close correlation with serum values. Because Whatman 903 cards are the most 
commonly-used filter paper for DBS collection and preservation in clinical care 
and research, this finding has important implications for future work among more 
than 700 million individuals living in areas in which schistosomes are endemic. 
First, we have validated a simple means by which DBS that have been banked for 
cohort studies can be tested to determine whether pre-existing schistosomiasis 
was a risk factor for later patient events, such as subsequent HIV acquisition or 
development of cancer. In addition, our work demonstrates an opportunity to 
enhance both patient care and clinical research by coupling schistosome testing 
with HIV- or malaria-related testing in the same DBS. The ability to test for 
CAA in DBS represents a streamlined way in which schistosome testing can be 
Figure 2. Serum CAA versus Dried Blood Spot Samples 
after Eight Years of Storage.
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enhanced, either on its own or in concert with other projects, thereby increasing 
attention to this neglected parasitic infection.
In contrast to a prior report that very little CAA could be detected in DBS stored 
at room temperature for longer than three months (15), we successfully eluted and 
quantified CAA in Protein Saver cards that had been stored at room temperature 
for approximately eight years. Our finding that the CAA sensitivity remained high 
in eight-year-old spots suggests minimal degradation of CAA during long-term 
storage at ambient temperatures on these optimized storage papers. While long-
term Protein Saver card storage at ambient temperatures has been demonstrated 
to be suboptimal for subsequent study of nucleic acids (24) and antibodies (25), 
our findings support the conclusion that this is not an issue for this schistosome-
derived glycoprotein that is stable enough to be detected in Egyptian mummies 
(14).
Our results support and further the findings previously reported for CAA testing 
in DBS on other paper types—that CAA is indeed detectable in DBS but that it is 
incompletely eluted. In order to achieve CAA ratios comparable to those obtained 
from 20 µL of serum, we had to use an area of blood on the Protein Saver card 
that corresponded to approximately 30 µL of serum. An earlier study similarly 
reported recovering less than one-third of a known quantity of CAA from several 
other common filter papers (15). In contrast, 80-100% of the original CAA 
quantity was obtained from blood dried onto an inert polypropylene fiber web 
matrix (15). Investigators postulated that poor CAA recovery from filter papers 
compared to the matrix was related to the papers’ higher fiber densities, smaller 
pore sizes, and the interaction of CAA with reactive hydroxyl and carboxylic acid 
groups on the hydrophilic surface of the cellulose. Whatman 903 Protein Saver 
cards are similarly made from nearly pure cellulose, with a comparable pore size 
and a larger fiber density than papers previously tested (26). Our data shows that 
these challenges, while not trivial, become surmountable by increasing the area 
of blood spot used. Our prolonged overnight elution, as compared to 30 minutes 
in the prior study (15), may also be an important factor in maximizing recovery.
Our study had to deal with some practical limitations. Mainly, due to small sample 
size and the finite quantity of sample available from DBS, we were not able to test 
multiple iterations of our elution protocol in order to optimize the performance 
of CAA testing in DBS. It is likely that the protocol can be further optimized to 
increase sensitivity (e.g. extended (24-hour) elution time, larger elution-volume 
to card-surface ratio, elevated temperature and shaking, and use of detergents 
were not explored to the fullest). We also did not have microscopy data from stool 
or urine, and therefore designed this study to determine the correlation between 
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CAA testing in DBS and in serum rather than to compare CAA testing in DBS 
with parasitological data.
In conclusion, our work demonstrates the feasibility and reliability of CAA testing 
in DBS collected onto Whatman 903 cards. Such DBS collection is a cost-effective, 
convenient way to obtain, transport, and store blood samples. Many of the remote 
resource-poor settings in which the simplicity of DBS collection is most needed 
are also those plagued by schistosomiasis. Our work opens new avenues for 
testing these at-risk populations, with the flexibility to test both recent samples 
for clinical care and older samples, regardless of storage temperature, to explore 
research questions. Increased implementation of CAA testing has the potential 
to benefit 700 million people living in schistosome-endemic areas through 
exploration of new hypotheses related to interactions between schistosomiasis, 
co-infections, and non-communicable diseases in these vulnerable individuals. 
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Schistosomiasis affects over 230 million people worldwide, 90% of whom live in 
sub-Saharan Africa (1). Data suggests helminthic infections like schistosomiasis 
may hasten HIV progression in co-infected patients (2,3). Helminths induce 
chronic immune activation, shifting from a T-helper cell type 1 (Th1) to type 
2 (Th2) immune response. Th2- lymphocytes down-regulate cytotoxic effects 
of CD8+ T-lymphocytes, leading to an altered cytokine profile with increased 
viral replication (4–7). Studies have shown that treating ascariasis or filariasis 
improves CD4+ T-cell counts (CD4 counts) and viral loads in HIV-infected 
patients (8,9).
Little research has explored the specific interaction between schistosomiasis 
and HIV, but one study yielded concerning results. Antiretroviral therapy 
(ART)-naive HIV-infected patients with schistosome co-infection who were 
randomized to delayed anti-schistosome treatment with praziquantel after three 
months had larger increases in HIV RNA levels and greater declines in CD4 
counts than patients treated immediately (10). Despite this possible interaction, 
schistosomiasis screening is not currently recommended for HIV-infected 
patients in many endemic countries, including Tanzania. Also, no study has yet 
assessed impact of schistosomiasis on ART response.
We hypothesized that schistosome infection may adversely affect HIV-infected 
patients’ responses to ART. We conducted a retrospective cohort study to explore 
this issue at Bugando Medical Centre (BMC) near Lake Victoria in Tanzania, 
where schistosomiasis is hyper-endemic.
Methods
Study participants
This study was conducted from August-December 2011 at BMC’s HIV clinic. 
HIV-infected adults who had taken ART for 6–15 months were enrolled 
serially. Patients who had received praziquantel since beginning ART, or who 
were currently receiving antituberculous therapy and therefore had another 
concomitant infection that could cause CD4 decrease (11), were excluded.
Data collection
Demographic information was collected by structured questionnaire. Baseline 
data (at ART initiation) was obtained from the patient database, including CD4 
count, weight, and height.
At the time of enrollment and sample collection, we measured CD4 count by 
FACSCount system (BD Biosciences, San Jose, CA), height, and weight. We used 
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the World Health Organization (WHO) definition of immunological failure as 
either CD4 count falling below baseline or CD4 count persistently <100 cells/
mm3 (11).
Patients provided single mid-day stool and urine samples. Kato-Katz stool smears 
were prepared using 41.7mg templates (Vestergaard Frandsen, Switzerland). 
Five slides were prepared from different sites of each stool sample, which has a 
reported sensitivity comparable to examination of specimens from different days 
(12). A trained parasitologist quantified S. mansoni eggs/gram.
Urine was examined microscopically and tested for circulating cathodic antigen 
(CCA) (Rapid Medical Diagnostics, South Africa). CCA, an antigen secreted into 
the bloodstream by adult schistosomes during active infection, is detectable in 
urine by rapid reagent test strip (13,14). Schistosome infection was defined as 
ova in stool or urine and/or a positive CCA test, a strategy shown to increase 
diagnostic sensitivity without compromising specificity for low-intensity S. 
mansoni infections typical of adult populations (15).
Data analysis
Logistic regression models (adjusting baseline CD4 count, which we call ‘bivariate 
analysis,’ and multivariate analysis adjusting for additional factors) were used 
to examine factors associated with immunological failure. In all models, we 
adjusted baseline CD4 count for more valid analyses, noting that the outcome, 
immunological failure, is defined as a function of baseline CD4 count. We used 
backward elimination, deleting variables with the largest p-value one by one, to 
reach a final parsimonious model including all factors with p<0.05.
We used analysis of covariance (ANCOVA) to compare CD4 count increases 
between groups with and without schistosomiasis while adjusting for baseline 
CD4 count (16). Two-sided 95% confidence intervals and p-values were used 
throughout. Data were analyzed using Stata IC/10.1 (College Station, Texas).
Ethics
Ethical approval was obtained from BMC and Weill Cornell. Patients diagnosed 
with schistosomiasis immediately received praziquantel (40mg/kg).
Results
Patient characteristics
Of 364 eligible HIV-infected outpatients coming to clinic during the study 
period, one had received praziquantel and 10 were being treated for tuberculosis. 








































































































































































































































































































































































































































































































































































































Table 1. Baseline factors associated with immunological failure in HIV-
infected adults after at least six months of antiretroviral therapy.
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Of the remaining 353 patients, 351 provided written informed consent, urine, 
and stool and were enrolled. Of these, 248 (71%) were females. The median age 
was 36 (interquartile range 31–43) years. Over 90% had primary school education 
or less, and >80% were unemployed or petty traders. Baseline CD4 count at ART 
initiation was 173 (76–249) cells/μL and baseline body mass index (BMI) was 21.6 
(19.7–23.9) kg/m2. Baseline WHO clinical stages were: Stage 1--54 patients (15%), 
Stage 2—130 (37%), Stage 3—127 (36%), Stage 4—40 (11%). Patients had taken 
ART for a median of 338 (265–376) days.
Prevalence of schistosomiasis
Schistosomiasis was diagnosed in 97 patients (27.6%). All 97 were CCA-positive, 
and 46/97 had ova in urine or stool. All 46 of these had Schistosoma mansoni, and 
one had concurrent S. haematobium. All 46 patients with schistosome ova were 
CCA-positive, and 41/46 had low-intensity infections of <100 eggs/gram of stool.
Outcomes after ART
The median CD4 count change was +190 (104–303) cells/μL. Median BMI 
increase was +1.4 kg/m2. Twenty-five patients (7%) met ≥1 WHO criterion for 
immunological failure: 22 had CD4 counts below baseline and 7 had CD4 counts 
persistently <100 cells/μL.
Factors Associated with Immunological Failure
Table 1 shows univariate and multivariate analyses. In the multivariate model, 
education and baseline BMI were moderately associated with immunological 
failure (p=0.04), while schistosome infection was strongly associated (Odds ratio 
4.6 [95% confidence interval: 1.9–11.2], p=0.0009).
Secondary analysis by ANCOVA, with change in CD4 count as a continuous 
outcome, showed that CD4 count increase on ART was significantly associated 
with schistosome infection, baseline CD4 count, and age in the multivariate, 
Binary variables are reported with number and percent, and continuous variables 
are reported with median and interquartile range. For continuous variables/
factors, odds ratios correspond to that for a one unit increase in variable (e.g., age 
50 to 51).
*In regression models, education was modeled as a continuous variable.
**In all regression models, baseline CD4 was always adjusted as the outcome is 
defined as a function of baseline CD4. Thus, in bivariable analyses, results for 
baseline CD4 are summarized as a range rather than a single number.
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parsimonious model. These effects were most strongly driven by schistosome 
infection status, with an estimated difference of 65.5 cells/μL in CD4 count 
change between those with and without schistosomiasis (p=0.0004). Unadjusted 
and adjusted mean CD4 count changes were +163 versus +226 cells/μL and +161 
versus +227 cells/μL, respectively.
Discussion
Among these adult HIV-infected outpatients living in a schistosome-endemic 
area, nearly one-third had active schistosome infection. Odds of developing 
immunological failure were four times greater in patients with schistosome 
co-infection. To our knowledge this is the first study assessing the association 
between schistosomiasis and ART treatment failure. Our findings have major 
implications for ART management in millions of HIV-infected outpatients living 
in schistosome-endemic areas who are managed based on immunological and 
clinical criteria because viral load measurements are not routinely available.
Schistosome-infected patients also had significantly lower CD4 count increases 
on ART than schistosome-uninfected patients. More frequent immunological 
failure and smaller CD4 count gains in schistosome-infected patients could both 
be explained by chronic helminth-induced Th2-type immune activation, which 
may permit increased viral replication (4). Our work extends findings of a study 
in which Zimbabwean HIV- and schistosome-co-infected patients randomized 
to delayed praziquantel had larger HIV RNA increases and CD4 count declines 
than patients treated immediately (10). Other studies have suggested similar 
effects from other helminth infections, but not unanimously (8,9,17). Notably, 
other studies have not explored helminth infections’ effects on patients receiving 
ART.
Our finding that schistosomiasis is both common and associated with 
immunological failure supports implementation of schistosomiasis screening at 
ART initiation. Unfortunately, stool and urine testing alone, particularly when 
done as the thin preparation of stool and unfiltered urine typical of many African 
clinical laboratories, has low sensitivity for detecting schistosome ova. Antigen 
tests including urine CCA used in this study may provide rapid, more sensitive 
screening for schistosomiasis, particularly since HIV-infected individuals may 
excrete fewer eggs (18,19). Further operational research is needed to determine 
costs, benefits, and optimal screening strategies.
In a previous study that compared baseline characteristics of schistosome-infected 
and uninfected HIV-positive patients, schistosome-infected patients had higher 
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baseline CD4 counts and CD4:CD8 ratios but comparable viral loads (6). Patients 
in that study were ARTnaive, as were ours during baseline investigations. Neither 
study observed other baseline differences between patients with and without 
schistosomiasis that might explain the higher CD4 counts. Schistosomiasis may 
cause distinct immunological alterations in peripheral blood CD4+ T-lymphocyte 
subsets, and these alterations may impair patients’ responses to ART. Additional 
studies are needed to better-characterize peripheral blood CD4+ T-lymphocyte 
subsets in HIV and schistosomiasis co-infection.
The retrospective nature of our study is an ethically-necessary limitation since 
our hypothesis could not be studied prospectively. Based on the Zimbabwean 
study showing worse virological and immunological outcomes in HIV-infected 
patients with untreated schistosomiasis, it would not have been ethical to leave 
schistosomiasis untreated in patients initiating ART. Another limitation was 
our inability to test viral loads. Without virological data, we cannot determine 
whether schistosomiasis was associated with immunological failure alone or with 
concomitant virological failure. We plan further studies using viral load testing 
to explore this question.
In conclusion, nearly one-third of our Tanzanian HIV-infected outpatients had 
schistosome infection. Schistosome infection was significantly associated with 
immunological failure and poorer CD4 count gain following ART use. Untreated 
schistosomiasis may be a major cause of immunological failure among HIV-
infected patients in schistosome-endemic areas. Further studies are needed to 
investigate whether this represents an immunological phenomenon or true 
virological failure, and whether screening and treatment for schistosomiasis 
among HIV-infected patients will improve response to ART. This is an urgent 
finding with major implications for ART management in resource-limited 
settings, where choices of antiretroviral medications are limited and success of 
patients on first-line ART must be maximized.
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Introduction
Newborns infected with HIV before, during, or shortly after delivery have high 
mortality with 50% dying before one year of age, and 20% of these early deaths 
occurring between the first and third months of life (1). Early diagnosis and 
treatment reduces mortality by up to 76% (2), but neonatal diagnosis is difficult. 
Antibody-based rapid HIV tests frequently yield false positive results because 
of transplacental transfer of maternal antibodies that can persist in the child’s 
circulation for up to 18 months (3). For this reason, polymerase chain reaction 
(PCR)-based viral nucleic acid tests are recommended instead (4). At present, 
viral DNA or RNA can only be identified in a laboratory with the technical 
capacity to perform PCR.
The demonstration that HIV RNA and DNA can be detected in dried blood 
spots (DBS) revolutionized newborn HIV testing in resource-poor areas in which 
laboratory facilities are limited (5). Unlike serum samples that must either be 
tested within hours of collection or frozen for transport, DBS can be stored in 
warm, humid climates and later transported to reference laboratories for testing 
while still yielding accurate results (6). These findings led the World Health 
Organization to endorse DBS testing as the single screening tool for all infants 
born to mothers with HIV infection or unknown HIV status (4). Given that 
DBS are additionally now being used for viral load monitoring, drug resistance 
genotyping and even neonatal screening for hereditary diseases (7–9), ensuring 
the feasibility and reliability of this system is crucial. 
In northwestern Tanzania, where we work, Bugando Medical Center (BMC) 
serves as the reference laboratory for early infant diagnosis (EID) of HIV-exposed 
children. The laboratory’s EID program was first piloted in 2006 (10). BMC’s 
laboratory serves a population of 13 million people, receiving DBS from 96 clinics 
in the seven regions surrounding the medical centre. 
The lead investigator for this project (S.M.) is a pediatric nurse providing 
primary care to HIV-infected children at a clinic in Magu, Tanzania, located ~70 
kilometers east of the Bugando laboratory. She grew frustrated with the protracted 
turn-around time (TAT) for results of DBS collected from HIV-exposed infants 
attending the clinic. DBS collected during infants’ six-week immunization visits 
were still pending at children’s subsequent ten-week visits. Sometimes mothers 
never received their infants’ results. These delays in diagnosis led to preventable 
deaths,  particularly given the ~30% mortality of perinatally-infected infants 
during the first six months of life (1) and the advanced stage of HIV disease that 
affects approximately half of HIV-infected infants who do not start ART before 
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12 weeks of age (11). She therefore designed a systems improvement project to 
identify and address the root causes of these delays.
Systems Improvement Project Methodology
In the project’s first phase, each step in the EID DBS process was carefully mapped. 
Five steps in the process between collection of a DBS and reporting of the result to 
a caregiver were identified. Each time a DBS was collected, infant demographics, 
date of collection, and date of shipment to Bugando were recorded consecutively 
in a log book in Magu. When the DBS result was returned, nurses in Magu used 
the lab report to fill in the dates for the remaining steps in the process. 
The study’s lead investigator collected this data from the handwritten log book 
and entered it into Microsoft Excel. Minor errors in dates with an obvious 
alternative were corrected (e.g. correct month and day but wrong year, or aberrant 
month in an otherwise consecutive series of dates). Ambiguous dates without an 
obvious alternative were recorded as missing data. The duration of each step was 
calculated based on the available (non-missing) data.
Two significant clinical process endpoints were identified: 1) TAT between 
DBS collection and return of test result to the Magu clinic (when the result is 
available to the clinician and the local staff) and 2) TAT between DBS collection 
and communication of test result to the infant’s mother. Fig 1 demonstrates the 
5 steps in this process, and lists the median number of days between each step 
during a baseline assessment in 2011. 
Figure 1. Flow diagram of steps required for rural dried blood spot HIV viral load 
testing and median times to completion at baseline.
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In the second phase, the team implemented sequential interventions to decrease 
the time of individual steps. After each intervention, the team measured resultant 
duration of each step as well as the cumulative TAT between DBS collection and 
the two designated endpoints. Consecutive interventions were designed and 
implemented based on observations and experience from prior interventions 
using a systems improvement method based on the Plan-Do-Study-Act model (12).
Data analysis was performed using Stata Version 13 (College Station, Texas). Due 
to non-normal distribution of the data, medians and interquartile ranges (IQRs) 
were calculated. Overall differences between groups were determined using the 
Kruskal-Wallis test. If the p-value was less than 0.10, we subsequently performed 
between-group comparisons using the Wilcoxon rank-sum test.
Results
Between July 2011 to October 2013, 383 HIV-exposed infants were seen at 
Magu Health Centre and had DBS collected and sent to the Bugando reference 
laboratory for testing. Sixteen infants were entered into the Magu log book but 
had no further dates recorded and were excluded from further analysis. Infants 
were a median of 61.5 (IQR 39-133.5) days old at DBS collection. Baseline data 
were collected from July 2011 to January 2012 for 85 patients for whom DBS 
were sent, and these data are presented in Fig 1. The median overall baseline 
TAT from DBS collection to result availability at Magu was 55 (IQR 35–68.5) 
days, and TAT from DBS collection to result communication to mothers was 63 
(IQR 35-88) days. Of note, due to the skewed distribution of the data, the total 
median turn-around times differ from the sum of the median values presented 
for each step in Fig 1. 
We first attempted to decrease time between arrival of DBS at BMC and completion 
of testing (Step 2, Fig 1). The laboratory tests 44 samples per day in a single run 
on the COBAS Ampli-Prep/Taqman System (Basel, Switzerland) and receives 150-
200 samples per day from health centers. Samples testing positive on the first run 
are repeated the following day. Due to staffing levels, the laboratory was unable to 
complete a second run per day on the machine. Our study team therefore turned 
its focus to other steps. Indeed, from 2011 to 2013 the median number of days that 
samples spent in the BMC laboratory actually increased slightly (Table 1).
We next attempted to decrease time between completion of testing at BMC and 
return of results to Magu (Steps 3 and 4, Fig 1). Beginning in February 2012, the 
study team provided a laboratory staff member with phone vouchers to call a 
nurse at Magu weekly and verbally relay results from the prior week. Verbal results 
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Table 1. Median (interquartile range) number of days required for sequential 
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were recorded in the Magu log book and acted upon, and they were subsequently 
confirmed when the written results arrived at Magu and were entered formally 
into the log book. This led to significant decreases in the time that the test result 
was ready in the lab waiting for transport (18 (IQR 10-34) days to 8 (IQR 5-13) 
days, p<0.001) and to the amount of time taken for the test result to be transmitted 
from the lab to Magu (3 (IQR 3-7) days to 1 (IQR 0.5-1) day, p<0.001). The overall 
TAT from DBS collection to return of result to Magu decreased, though not yet 
significantly, from the baseline value of 55 (IQR 38-68.5) days to 48 (IQR 43-65) 
days among patients who had blood spots collected from February to May 2012 
(p=0.87). The lack of significant decrease in cumulative TAT is likely attributable 
to the significant increase in time required for test performance in the reference 
laboratory (13 to 34 days, p<0.001). The team noted that, despite this improvement, 
18/51 results (35.3%) that returned to Magu were not communicated to mothers 
and room for improvement remained.
After June 2012, the team focused on two separate steps: time between collection 
of DBS and arrival at BMC (Step 1, Fig 1) and time between result arrival at 
Magu and result communication to mothers (Step 5, Fig 1). It was discovered that 
nurses at Magu were not sending DBS to Bugando until they had collected at least 
3-5 samples. Instructions to send DBS as soon as possible after collection were 
reinforced, and nurses began to ask drivers of hospital vehicles between Magu 
and Bugando to carry blood spots to the laboratory whenever possible (usually 
1-2 times weekly) rather than waiting to send samples in batches in a dedicated 
car from the Bugando HIV clinic. Median time between a DBS collection and 
arrival at Bugando decreased from 10 (IQR 4-17.5) days at baseline to 6 (IQR 3-9) 
days after June 2012 (p=0.001). This led to an overall improvement in median TAT 
from 48 (IQR 43-65) days during the previous intervention period to 38 (IQR 29-
51) days (p<0.001). 
After June 2012, the study team also partnered with an ongoing home visit nurse 
program in Magu in which clinic nurses spend one afternoon per week visiting 
homes in the community. The study team ensured that visiting nurses focused 
preferentially on visiting HIV-infected mothers to remind them to return to clinic 
to obtain their infants’ results. Additionally, nurses at the Magu clinic now leave a 
blank space on infants’ vaccination cards and fill in the DBS result when mothers 
obtain it. Taken together, these interventions led to consistent communication 
of results to mothers in 90.5% (95/105) of blood spot results that arrived at Magu 
after June 2012, compared with 47.2% (34/72) at baseline (p<0.001).
Since the project began, the overall TAT from DBS collection to return of 
results to Magu has decreased from a median of 55 (IQR 35-68.5) to 38 (IQR 
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29-51) days (p<0.001, Fig 2). 
Dates of DBS collection and 
timepoints continue to be 
recorded in the log book by 
the Magu nursing staff, and 
data from 2014 demonstrates 
that these levels have been 
sustained, with ongoing 
oversight from a nurse who 
visits Magu once monthly 
from Bugando but no 
further cost investment. 
The ongoing costs are 
weekly vouchers for phone 
calls (USD $1 per week); 
other interventions have 
built on and/or redirected 
existing systems at negligible 
incremental cost. For example, the visiting nurse program is not a new program 
but instead reprioritizes the goals of an existing visiting nurse program. Since the 
start of this project, 18 HIV-infected infants’ mothers have been notified of their 
results, and these babies have been started on lifesaving antiretroviral therapy.
Project Assessment and Discussion
Our work has demonstrated that significant improvements can be made in the 
implementation of neonatal HIV testing in a rural setting with dedicated attention 
and application of a simple, locally-driven system-improvement methodology. 
During this two-year project, the study team’s intervention decreased DBS 
TAT from 55 to 38 days, and improved result communication rates to mothers 
from 47% to 91%. These interventions required minimal incremental cost in the 
study setting and have been sustained. Our study team has now presented our 
experience to other nurses providing primary pediatric care in rural clinics in 
our region to equip them to devise their own locally-relevant solutions to address 
implementation problems at their respective health centres.
A major strength of our work is that it models the critical role for quality improvement 
interventions within HIV programming, and particularly how such interventions 
can and often should be driven by local health centre staff. Health workers caring 
for patients in rural settings have first-hand knowledge of system breakdowns and, 
often, can propose innovative, low-cost, sustainable ideas for improvement if given 
the opportunity to do so. In our case, our principal investigator initially sought to 
Figure 2. Turnaround times from dried blood spot 
collection until result available at health center (dashed 
line) or result given to mother (solid line).
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change procedures in the reference laboratory (largely beyond her control). When 
that proved impossible, she subsequently devised a series of simple solutions that, 
taken together, shortened the TAT by ~17 days, bringing major health benefits 
to her patients and empowerment to local staff. Such quality improvement work, 
in which locally-devised innovations promote “buy-in” and rejuvenation for 
overburdened staff, was recognized as a key factor in multiple successful quality 
improvement projects in South Africa (13).
To the best of our knowledge, no studies have been published on small scale, low-
cost systems improvement projects to EID such as ours. Three countries have 
published marked improvements in their EID TAT after large scale technological 
or logistical investment. Rwanda made multiple changes to their system, 
including integrating EID into the immunization program, instituting a national 
pickup system to collect samples twice weekly from facilities, and implementing 
an automatic SMS system that sends results back to the mobile phone of the 
provider who ordered the test and the laboratory technician at the facility where 
the DBS originated. This package of interventions decreased median TAT from 
DBS collection to return of results to the clinic from 144 to 20 days (14). Uganda 
invested in a national pickup system, providing a motorbike and driver for each 
of their collection hubs and a national SMS printer system that sends results back 
to the hubs automatically from the reference laboratory. Uganda’s TAT from 
DBS collection to return of results decreased from 49 to 14 days (15). Zambia 
piloted a similar automatic SMS system, and TAT from DBS collection to result 
communication to the mother dropped from 67 to 35 days (16). 
In contrast to these large projects, our work, at a fraction of the cost, demonstrates 
the feasibility of local interventions in achieving TATs comparable to those 
reported through expensive, country-wide systems. It is our hope that other local 
clinics will use our work as a model to devise low-cost action plans relevant to 
their own contexts. In our case, simple changes such as writing reminders to 
obtain results on children’s health cards and providing a nurse with dedicated 
time to seek out caregivers who have not obtained their children’s results were 
effective interventions that required investment of relatively little money and 
time. Of note, Magu benefits from existing infrastructure like the visiting nurse 
program and a close transportation connection with BMC that might not be 
present in other settings. We outline key barriers and opportunities for change in 
Table 2. We recognize that this project’s focus on neonatal DBS testing represents 
only one aspect of highly complex prevention of mother to child transmission of 
HIV (PMTCT) programs. But improving this aspect of PMTCT programs needs 
to be a nonnegotiable, urgent goal.
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Table 2. Barriers to Expeditious Dried Blood Spot Testing and Potential 
Solutions.
Delayed transport from collection site to central laboratory
Problems Solutions
1) Busy health center staff 
responsible for coordination of 
transport
1) Shift burden of collection of samples 
to be transported to a driver rather 
than health center staff
2) Health center staff trying to 
decrease costs by shipping more 
samples at once
2) Standardize and routinize specimen 
pick-up at regular, frequent intervals
3) Emphasize to health center staff the 
larger cost of later seeking out patients 
whose results returned late
Delayed transmission of results to health centre
Problems Solutions
1) No person in laboratory 
responsible for result transmission
1) Place log or register in laboratory 
requiring documentation of result 
transmission
2) Laboratory’s emphasis is 
maximizing number of test results 
rather than sending results
2) Implement measurement of time to 
result transmission in laboratory as a 
quality-control standard
3) Subsidize phone/SMS 
communication or institute automated 
SMS transmission method
Difficulty providing results to mothers/caregivers
Problems Solutions
1) Caregivers do not understand 
urgency of obtaining results
1) Improve counseling provided to 
caregivers at time of dried blood spot 
collection
2) Many caregivers return routinely 
for vaccinations but not at other 
times
2) Ensure that home visit/outreach 
nurse reminds caregivers to return for 
results
3) Some caregivers grow frustrated 
with returning to clinic only to learn 
that results have still not arrived
3) Insert space for result on child’s 
health card so caregiver notices that it 
is incomplete
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Despite these successes, our work also demonstrates the need for an ongoing 
discussion about the feasibility of relying on such a complex multi-step process 
for provision of laboratory testing in remote settings. Our local neonatal testing 
algorithm is a five-step process that works smoothly only when laboratory supply 
and functionality, transport, communication, and patient follow-up systems are 
simultaneously operational. A breakdown at any step creates an impasse and 
delays HIV diagnosis for hundreds of children in northwest Tanzania. In the face 
of these challenges, the growing optimization of point-of-care nucleic acid testing 
for infant HIV diagnosis offers hope that EID will eventually become a simple, 
streamlined service that provides same-day results, allowing earlier initiation of 
ART for infected infants and earlier cessation of ART for uninfected ones (17,18). 
In conclusion, our work highlights the major importance of working, both on local 
and national scales, to improve the implementation of HIV programs with proven 
effectiveness. With the impending expansion of DBS testing for HIV viral load 
monitoring and genetic disease screening, our successes and challenges highlight 
the importance of a realistic assessment of this system’s limitations. Yet we hope 
that our experience also engenders hope that simple, practical interventions 
can have real impact on the health and well-being of patients in resource-poor 
settings. We continue to strive towards additional improvements in TAT, with 
particular focus on increasing the percentage and frequency of mothers returning 
for results by providing community education on the importance of EID. We 
also are now evaluating the percentages of infants who are ultimately started on 
lifesaving ART, which is the ultimate goal of efforts to expedite EID. We share 
our experience in hopes that we, other local clinicians, and national leaders will 
resolve to work together to streamline and/or de-centralize this system in order 
to make essential diagnostic testing more accessible.
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CHAPTER 8
SUMMARIZING DISCUSSION
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The work presented in this thesis was conducted in Mwanza, Tanzania, and 
was inspired by the tremendous burden of disease in the Tanzanian population. 
Neglected tropical diseases such as schistosomiasis, which may be seen once or 
twice in a lifetime by a physician practicing in a high-income country, are weekly 
if not daily diagnoses in health centers and hospitals, and disproportionately 
affect younger patients of lower socioeconomic status. HIV, though a worldwide 
epidemic, has also particularly afflicted sub-Saharan Africa. Over 1 in 20 
Tanzanian adults is HIV-infected, and nearly 60% of these are young to middle-
aged women (1). Moreover, like many other illnesses in Tanzania, HIV is often 
not diagnosed until patients have developed advanced disease, at which point 
it may be too late.
The goal of the thesis has been to conduct studies that, ultimately, will lessen the 
disproportionate burden of infectious diseases in sub-Saharan Africa, whether by 
preventing them altogether, by diagnosing them earlier, or by working to alleviate 
complications attributable to co-infections. The work has focused primarily on 
schistosomiasis and HIV in Tanzania, building on prior work in the field from 
Zimbabwe, Kenya, and several other countries in sub-Saharan Africa.
The discussion will be divided into three sections: Schistosomiasis and HIV Risk; 
Managing Schistosomiasis-HIV Co-Infection; and an Implementation Science 
Study to Improve Early Infant HIV Diagnosis. Each of these topics will be first 
discussed with reference to the contribution made by the findings presented in 
the preceding chapters, and then will turn towards an examination of the needed 
next research steps.
I. Schistosomiasis and HIV Risk
Schistosoma haematobium Infection as a Risk Factor for HIV Acquisition
S. haematobium infection was postulated to be a risk factor for incident HIV 
infection at least as early as 1994, long before Kjetland and colleagues published 
their clinical findings from Zimbabwe (2). A causal relationship between S. 
haematobium infection, usually acquired in childhood well before sexual debut, 
and HIV infection is biologically plausible for a number of reasons, as outlined in 
the introduction. Kjetland and colleagues documented for the first time a clinical 
association between S. haematobium infection and HIV in Zimbabwean women 
(3). Because of the biologic plausibility and multiple other lines of evidence 
suggesting that schistosomiasis could be a risk factor for HIV acquisition, the 
Zimbabwe findings were compelling. However, that work was conducted at a 
single site that may have had uniquely high rates of both S. haematobium (39%) 
and HIV (25%) infections. In addition, due to the study’s cross-sectional design, 
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it was not able to demonstrate that S. haematobium infection preceded HIV 
infection, but merely that the two were significantly associated with one another.
Our work presented in Chapter 2 provides strong new, independent evidence in 
support of the HIV-S. haematobium association. We enrolled 457 women living 
in eight rural villages in Tanzania; the prevalence of S. haematobium infection 
varied by village from 0 to 11% and the overall prevalence of HIV infection was 
5%. In this moderately-endemic setting, S. haematobium infection was again 
shown to be strongly associated with HIV, with an OR of 4.0 [IQR, 1.2-13.5]. Our 
OR was comparable to the OR of 2.9 reported by Kjetland and colleagues, despite 
the markedly higher prevalence of both S. haematobium infection (40-50%) and 
HIV infection (28%) that were observed in Zimbabwe (3). Thus our study provided 
important corroboration of the Zimbabwe study, because there now exist two 
separate studies, conducted in different countries with varying intensities of S. 
haematobium and HIV infections, both demonstrating the disturbing finding 
that women with S. haematobium infection have a 3-4 -fold higher odds of being 
HIV-infected than women without S. haematobium infection. 
Worry about the potential HIV risk caused by S. haematobium infection is 
further increased by results reported in our longitudinal study in Chapter 4. We 
documented that praziquantel treatment of urogenital schistosomiasis resolved 
neither the gynecologic abnormalities associated with S. haematobium infection, 
nor the presence of the parasite as demonstrated by detectable schistosome DNA, 
6 months after treatment. Our work extended others’ findings that the clinical 
signs of schistosomiasis did not resolve up to 12 months after treatment (4,5) by 
documenting that, additionally, schistosome DNA could be identified in both 
urine and cervical lavage. Women in our study had a median age of 22 [IQR, 20-
28], and one-fourth reported never being previously treated for schistosomiasis. 
Many of them may therefore have resembled the older Zimbabwean women, 
described by Kjetland and colleagues, in whom praziquantel treatment after 
age 20 was not effective in reversing cervical pathology (6). If S. haematobium 
infection is indeed a risk factor for HIV acquisition, and if the effects that lead to 
increased HIV susceptibility are incompletely reversed when treated according to 
the current standard of care, this is an area for urgent future research.
Moreover, if S. haematobium is a risk factor for HIV acquisition and it is at least 
partially irreversible, then this must prompt a redoubling of efforts to eradicate 
the disease. Vaccines against S. mansoni are currently in Phase I clinical trials 
in the United States and Brazil, while a Phase III clinical trial for a vaccine for 
S. haematobium is expected to be completed shortly in Senegal and Nigeria 
(7). The vaccine development process for schistosomiasis and other neglected 
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tropical diseases has been fraught with challenges including the complexity 
of the eukaryotic parasite genome, the difficulty measuring effectiveness 
in infections that cause more disability than death, and the dearth of fully-
translatable animal models (7). In the interim until vaccines become available, 
early and regular provision of anti-schistosome medications to prevent disease 
morbidity must be urgently prioritized, particularly since only approximately 
15% of people who needed treatment actually received it in 2013 (6,8,9). As the 
current gold-standard medication praziquantel is made more widely available to 
populations in need, its administration must be accompanied by robust studies 
to determine optimum dose and frequency of administration, as well as to 
quantify clinical effectiveness. This is particularly important given the findings 
of a recent Cochrane review that treating soil-transmitted helminth infections 
among children did not improve mean nutritional status, cognition, hemoglobin 
level, or survival (10). The ultimate aim, listed as one of the 2015-2030 United 
Nations Sustainable Development Goals is to eliminate schistosomiasis and 
other neglected tropical diseases altogether (11).
Other investigators have also explored additional implications of the association 
between S. haematobium and HIV infection. Men with S. haematobium 
infection have been shown to have bloody ejaculate containing higher levels of 
lymphocytes and inflammatory cytokines than men without schistosomiasis, 
which may facilitate HIV transmission in men with both S. haematobium and 
HIV infections (12). For women living in endemic settings, S. haematobium 
infection may render them doubly susceptible to HIV acquisition, due to both 
their own increased susceptibility and to the increased HIV transmissibility of 
their S. haematobium-infected male partners. It has been recently suggested that 
the failure to account for S. haematobium as a potential HIV risk factor may have 
been a major confounding factor in 8 randomized controlled trials of treatment 
of STIs to prevent HIV acquisition in sub-Saharan Africa (13). In fact, in several 
of the studies, “control” treatment included albendazole or provision of improved 
sanitation—both of which would effectively decrease S. haematobium infections 
and bias the study towards a null result. If S. haematobium infection does indeed 
increase the odds of HIV acquisition by 3-4-fold, as in these two clinical studies, 
then the effect size of S. haematobium infection is comparable to the increased 
odds of HIV acquisition attributable to STIs (14) and S. haematobium infection 
could certainly have obscured the effects of STI treatment in these randomized 
trials.
Schistosoma mansoni Infection as a Risk Factor for HIV Acquisition
The findings described in Chapter 3 were surprising. Our hypothesis had been 
that S. haematobium increased HIV susceptibility predominantly by causing 
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lesions in the genital mucosa. However, we observed that women with S. mansoni 
infection also had an approximately four-fold increased odds of HIV infection, 
and that increasing intensity of S. mansoni infection, as measured by CAA level, 
was strongly and significantly correlated with the prevalence of HIV infection. 
One other study, performed in fishing villages in Uganda, also suggested that 
S. mansoni could be associated with HIV acquisition. In that study, HIV-
infected individuals living in an area endemic for S. mansoni were found to more 
frequently have antibodies to schistosome antigens than did HIV-uninfected 
individuals (15). As with our study, the Uganda study was cross-sectional and 
unable to demonstrate which infection preceded the other. The Uganda study also 
relied on an antibody test that can be positive both during and after infection, in 
contrast to the CAA assay that we used, which is positive during active infection 
and falls rapidly after treatment (16,17).
In contrast to our findings, two recent clinical studies have reported no 
association between S. mansoni and HIV infection, but they have been limited by 
methodological issues. Mazigo and colleagues screened 1,785 adults in Tanzanian 
fishing villages for HIV and S. mansoni infections, and found no association 
between these infections (adjusted OR 1.01 [IQR 0.84-1.21]) (18). This study relied 
on a single Kato-Katz smear and therefore may have missed lighter infections, 
which is notable given several reports that HIV-infected individuals may 
excrete fewer schistosome eggs (19,20). Impaired egg excretion by HIV-infected 
individuals would result in misclassification of some HIV-infected patients 
as being negative for S. mansoni infection, thereby biasing the study towards a 
negative finding. Sanya and colleagues in Uganda tested 1,412 adults using both 
a single Kato-Katz smear and a rapid Circulating Cathodic Antigen (CCA) point-
of-care test (21). They found no significant relationship between S. mansoni and 
HIV infection by stool microscopy (OR 1.04 [IQR 0.74-1.47], p=0.81). CCA testing 
was performed in only 650 individuals, yielding an OR for association with 
HIV infection that trended towards significance (OR 1.53 [0.78-3.00], p=0.19). 
Importantly, this sub-analysis only had the power to detect a difference of more 
than 10% in the prevalence of S. mansoni infection using CCA as the diagnostic 
tool, so the authors’ conclusion that their study demonstrates no association 
between S. mansoni and HIV infection raises questions.
Strong animal data from rhesus macaques clearly demonstrates that macaques with 
S. mansoni infection are more susceptible to simian HIV (SHIV) infection than 
uninfected macaques. Macaques have been previously demonstrated to be a robust 
model for HIV infection in humans, with macaques exhibiting parallel differential 
transmission risks across various mucosae and similarly slow progression of SHIV 
after infection (22,23). Macaques were inoculated rectally with increasing doses 
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of SHIV until they ultimately developed systemic SHIV infection. Macaques 
chronically infected with S. mansoni (n=8) developed SHIV at a median inoculum 
that was 17 times lower than macaques without S. mansoni (n=9) (p<0.001) (24). 
Median peak SHIV viral load was also >1 log copies/ml higher in S. mansoni- 
infected macaques than the macaques without S. mansoni (p=0.004). Of note, 
no significant difference in inoculum size or viral load was found when the 
experiment was repeated using intravenous inoculation instead of rectal mucosal 
inoculation (23). These findings directly implicate changes in the rectal mucosa, 
rather than in the systemic circulation, as the major contributors to increased 
HIV susceptibility in macaques with S. mansoni infection. 
Our findings in women with S. mansoni, together with these elegant macaque 
studies, have led us to reformulate our hypotheses about the mechanisms of HIV 
susceptibility in the setting of schistosome infection. It seems very likely that the 
epithelial breaches incited by S. haematobium ova migrating through the cervix 
are an important contributor to HIV risk. In addition, because S. mansoni eggs 
do not typically damage the genital mucosa in humans, we further postulate that 
schistosome infection triggers a generalized mucosal immune response, which 
may involve both rectal and genital mucosa. We hypothesize that this mucosal 
inflammation could lead to recruitment of HIV-susceptible cells to the mucosal 
surface and could thereby foster an immune environment in the mucosal tissue, 
at the initial site of HIV exposure, which is permissive to HIV infection. 
Next Steps: Schistosomaisis and HIV Risk
Therefore, a variety of evidence suggests that both S. haematobium and S. 
mansoni infections increase the odds of HIV acquisition. Mathematical modeling 
predicts that routine praziquantel administration to adults living in schistosome-
endemic areas would be highly cost-effective at $295 per HIV infection averted 
(25,26). However, until a robust prospective study quantitates the importance 
of schistosomiasis in HIV acquisition and definitively documents the causal 
relationship between schistosomiasis and HIV infection, schistosomiasis 
treatment will not be a public health priority for HIV prevention. 
Given the ethical complexity of conducting such a study prospectively, our 
work in Chapter 5 lays important groundwork that will make a retrospective 
longitudinal study possible. In Tanzania, serum samples have been stored as 
DBS from a cohort of 30,000 adults in rural villages who have been followed for 
over 20 years for HIV-seroconversion. In the proof-of-concept study described 
in Chapter 5, we documented that CAA can be reliably, accurately quantified in 
DBS as compared to serum, even in DBS that had been stored for up to 8 years. 
Our optimization of a technique to elute and quantify CAA from Whatman 903 
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paper, the most commonly-used DBS paper worldwide, opens new possibilities 
for other research studies on interactions between schistosomiasis and a variety of 
other communicable and noncommunicable diseases. We are currently using the 
technique that we have described to quantify CAA in banked DBS collected from 
adults prior to their HIV-seroconversion, and to compare this to the quantity 
of CAA in DBS from adults who did not HIV-seroconvert. We are additionally 
determining HIV-1 RNA viral load set-points as copies per milliliter of blood 
in new HIV-seroconverters who had and did not have schistosome infection at 
the time of HIV-seroconversion. This will provide human prospective data on 
the relationships between HIV susceptibility, schistosomiasis, and early HIV 
virologic control, with the potential to impact health policy and HIV prevention 
strategies throughout sub-Saharan Africa.
To investigate further the mucosal immunity hypothesis, studies are needed to 
identify and quantify differences in frequency, function, and types of immune 
cells in the cervical mucosal tissue of women with and without S. haematobium 
infection. This can ultimately be expanded to men and to individuals with and 
without S. mansoni. In addition, it will be important to determine whether, as 
reported with interleukin-17 production in mouse models, abnormal cytokine 
levels in tissue are reflected in peripheral blood (27). 
II. Managing Schistosomiasis-HIV Co-infection
Association between Schistosome Infection and Immunological Failure in HIV-
Infected Patients Receiving Antiretroviral Therapy
Growing evidence suggests that schistosomiasis may be not only a risk factor 
for HIV acquisition, but that it also may play an important role in HIV disease 
progression in individuals with HIV-schistosome co-infection. The single 
randomized trial in HIV-schistosome co-infected patients documented that 
patients treated with praziquantel had lower viral load increases than those who 
received delayed praziquantel treatment (28). A large randomized trial that treated 
helminth infections more generally and did not observe improvements in viral 
load was conducted in a setting with a low prevalence of schistosome infections 
(29). Neither of these trials enrolled HIV-infected patients on ART, which is a 
growing proportion of the HIV-infected population in sub-Saharan Africa. We 
hypothesized that schistosome infection could affect clinical outcomes and/or 
response to ART in HIV-infected patients and therefore performed the study in 
Chapter 6 to explore this question.
This project was conducted among 351 HIV-infected adult outpatients who 
had been taking ART for at least six months and resided in an area in which 
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S. mansoni is highly endemic. We reported that 28% of patients had concurrent 
schistosome co-infection, as documented by a positive CCA rapid test. This 
finding alone suggests the importance of screening and treating HIV-infected 
patients in our setting for schistosome infection in order to prevent schistosome-
associated morbidity and mortality. More troubling, HIV-infected patients with 
schistosome co-infection had a four-fold higher odds of having immunological 
failure than HIV-infected patients without schistosome co-infection. Patients with 
schistosome co-infection also had significantly lower CD4 count increases than 
those without schistosome co-infection after controlling for level of education, 
baseline CD4 count, and body mass index. Limitations of this study include our 
inability to study patients prospectively to determine the impact of untreated 
schistosome infection on immunological response, lack of information about 
other potential confounders including STIs, and the unavailability of HIV-1 RNA 
viral load level quantification at Bugando Medical Centre.
A study of CD4 counts in South African girls and young women demonstrated 
no significant differences in CD4 counts of girls with versus those without S. 
haematobium infection, as defined either by ova in urine or by gynecological 
abnormalities (30). In contrast to our study, in which all HIV-infected patients 
had been taking ART for at least 6 months, only approximately 15% of the HIV-
infected South African women were on ART. Another key distinction is different 
species of parasites (S. haematobium is endemic in South Africa and stool was 
not tested, while the vast majority in our study had S. mansoni). We also used 
both microbiological and antigen testing for diagnosis, which may have higher 
sensitivity for diagnosis of schistosome infection particularly in HIV-infected 
individuals who have been suggested to excrete fewer eggs (19). Therefore it is 
possible that the effects on CD4 counts are limited to S. mansoni infection, which 
has been associated with increased density of HIV-co-receptors on the surfaces 
of peripheral blood CD4 cells (31). Another possibility is that the plethora of 
systemic immune alterations caused by chronic schistosomiasis, including 
increased T-regulatory cells, increased Th2 immune response, and impaired 
innate Th1 immunity, impair the body’s ability to control viremia and in this way 
may precipitate true virological failure (32–34). 
Gaining a clearer understanding of these phenomena is urgent. Clinicians 
caring for most HIV-infected patients in sub-Saharan Africa still do not have 
access to gold-standard viral load monitoring for patients on ART, and are 
therefore dependent on CD4 counts to determine whether patients’ antiretroviral 
therapy is succeeding or failing, in accordance with the WHO’s clinical and 
immunological criteria for treatment failure (35). If schistosomiasis affects CD4 
count measurements, whether or not it actually impairs patients’ response to 
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antiretroviral therapy, then this will strongly impact treatment decisions for 
HIV-schistosomiasis co-infected patients in sub-Saharan Africa. 
Next Steps: Managing Schistosomiasis-HIV Co-infection
A major limitation of the work presented in Chapter 6 was our inability to 
measure viral loads. We were therefore unable to determine whether the 
immunological failure that was associated with schistosome co-infection was 
reflective of true virological failure in patients on ART. It is certainly possible 
that schistosome infection could increase the risk of virological failure, perhaps 
through its induction of a Th2-type immune environment that is permissive 
to viral replication (32,36). Conversely, it is also possible that schistosome co-
infection in HIV-infected patients could cause an immunological phenomenon 
that is independent of viral load suppression. Elliott and colleagues reported a 
difference in CD4:CD8 T-cell ratios between HIV-infected patients with versus 
without schistosome co-infection who were not on ART (37), and others have 
described a mechanism by which schistosome infection may induce the mild 
neutropenia observed clinically in patients (38). It is therefore possible that 
schistosome infection affects blood lymphocytes, and particularly that it could 
impair the ability of HIV-infected patients to mount high CD4 counts, even 
though they are successfully virologically suppressed. Impaired CD4 count 
recovery, even in patients with virological suppression, has been associated 
with increased AIDS-related clinical outcomes, AIDS-related mortality, and 
non-AIDS related mortality (39).
Therefore, a clear next step is to assess whether schistosomiasis is associated with 
virological failure and/or impaired CD4 count recovery in patients on ART. This 
could be examined using CAA testing in a cohort of patients for whom serum or 
dried blood spots were stored at the time of ART initiation. Because the majority 
of patients in sub-Saharan Africa are still managed based on CD4 counts, it is 
essential to ascertain whether immunological failure in the setting of schistosome 
co-infection represents true treatment failure, legitimizing a switch from first- 
to second-line ART. If it does not represent true treatment failure, millions of 
patients with HIV-schistosomiasis co-infection are at risk of unnecessarily being 
started on costlier, more toxic second-line ART.
Other studies in this field should further characterize the interactions between 
HIV and CD4 counts in patients with schistosome co-infection, particularly with 
regard to the rate of decrease following HIV acquisition and to the functionality of 
CD4 cells in preventing opportunistic infections. Moreover, regardless of whether 
schistosomiasis is associated with only immunological or both immunological 
and virological failure, future studies should assess whether patients with HIV-
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schistosomaisis co-infection have poorer outcomes. 
III. Implementation Science: Improving Efficiency of Early Infant Di-
agnosis of HIV by Dried Blood Spot Testing
Finally, our work in Chapter 7 provides an example of a low-budget implementation 
science project that, with sequential interventions, led to sustained improvement 
in early diagnosis for HIV-exposed infants. The local challenges that inspired 
this study typify the indispensable nature of quality improvement work to make 
scientific advancements in HIV care accessible in resource-limited settings. 
Importantly, the genesis of the project came from a local health centre nurse, 
who had experienced first-hand the frustrations of an ineffective system for HIV 
diagnosis. She proposed innovative, inexpensive ideas that decreased the turn-
around time from dried blood spot collection to result availability at the rural 
clinic from 55 to 38 days. While there remains room for additional improvement 
(38 days is still far from optimal), this project has invigorated local staff to devise 
new solutions that will both continue to shorten the turn-around time for DBS 
and will solve other local healthcare delivery problems. Moreover, this work 
can serve as a model for others seeking to address programmatic challenges in 
resource-poor settings.
Next Steps: Implementation Science Studies for Further Systems Improvement 
and to Maintain Impact
Implementation science is an essential aspect of providing HIV care and treatment 
in sub-Saharan Africa. As the WHO advises a shift toward viral load monitoring 
for management of HIV-infected patients on ART (40), the availability of viral 
load testing will continue to increase. In addition, point-of-care viral load tests, 
which could provide same-day results in HIV-exposed newborns, are also on 
the horizon (41,42). As these technologies and others like them are scaled up in 
sub-Saharan Africa, it will be vital that the scale-up is implemented in ways that 
ensure reliability, quality, and sustainability. Operational projects to assess the 
effectiveness and longevity of new programs must be integrated into the normal 
workflow of overburdened clinics in ways that empower, rather than add to the 
work burden of, local staff (43). 
Implementation science needs also to be a cornerstone of public health prevention 
measures. As public awareness grows regarding the relationship between 
schistosomiasis and HIV infection, it will be essential to ensure that individuals 
with schistosomiasis do not become stigmatized (44), whether due to public 
perceptions of their poverty or uncleanliness or to incorrectly-perceived sexual 
promiscuity. Uptake of routine anti-schistosome treatment, vaccination, or other 
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novel interventions to treat schistosomiasis and decrease HIV risk will likely not 
be maximized if public perceptions are not managed appropriately.
Concluding Remarks
This thesis began by describing the persistent burden of infectious diseases in sub-
Saharan Africa at a time when many wealthier parts of the world, having gained 
relative control of many infectious diseases, are now focusing on non-communicable 
diseases. It also touched on the morbidity and mortality caused by schistosomiasis, 
which, in and of itself, merits dedicated efforts at treatment. The bulk of the work 
presented in this thesis, displaying additional overlap between HIV infection and 
schistosomiasis, only further strengthens the imperative to treat patients suffering 
from this neglected tropical disease. Operational studies on other topics related 
to HIV prevention and diagnosis can serve as models for implementation science 
work that will improve upon the recent estimates that only 13% of those needing 
schistosomiasis treatment were treated in 2013 (9). Not only would treatment 
optimization decrease suffering from schistosomiasis itself, but its impact may be 
far broader if indeed schistosomiasis is a risk factor for HIV infection.
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English Summary
HIV infections have claimed more than 39 million lives since the HIV epidemic 
began more than 35 years ago. The HIV epidemic began in sub-Saharan Africa 
and continues disproportionately to affect this region. Though sub-Saharan Africa 
accounts for only ~12% of the world’s population, it is home to over two-thirds of 
global HIV infections, incident new infections, and 2/3 of HIV-attributable deaths.
It is well-known that individuals with infections such as gonorrhea, syphilis, and 
herpes simplex virus have a higher risk of becoming HIV-infected than individuals 
without these infections. In addition, people with HIV who have concurrent 
infections—including the sexually-transmitted infections mentioned above and 
tuberculosis—have higher concentrations of HIV-1 RNA in their blood. This 
increased HIV viral load causes these individuals with co-infections to transmit 
HIV more readily to their sexual partners, and also it speeds their progression from 
HIV to symptomatic AIDS and death in the absence of treatment. In addition, a 
growing body of evidence suggests that some tropical parasitic infections may 
also have these effects on HIV viral load and on an individual’s susceptibility to 
HIV. Thus it is plausible that co-infections such as these may have played a major 
role in the spread of the HIV epidemic in sub-Saharan Africa.
Schistosomiasis is a helminthic worm infection that affects 260 million people 
worldwide, 90% of whom live in sub-Saharan Africa. In Tanzania, where the 
research in this thesis was conducted, two species of schistosomes are highly 
endemic (Schistosoma haematobium and S. mansoni), with more than 50% of 
adults infected with one or both schistosome species in many regions. In and 
of itself, schistosomiasis causes significant morbidity and mortality, with an 
estimated 200,000 deaths annually and 3.31 million disability-adjusted life-
years. The possibility that it additionally impacts HIV transmission and disease 
progression render treatment and control of this neglected tropical disease even 
more urgent.
This thesis focuses on HIV prevention and disease management in sub-Saharan 
Africa. It will first describe population-based epidemiological work in Tanzania 
associating HIV with S. haematobium and with S. mansoni. Subsequent chapters 
focus on treatment of S. haematobium infection in women, where it causes genital 
tract disease, and on the effects of schistosome infection on immunological 
response to treatment in people living with HIV infection. The final chapters focus 
on implementation science work with high potential to improve HIV prevention 
and early diagnosis in Tanzania.
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In Chapter 1, the background and context of the work presented in this thesis 
is presented. The literature to date is reviewed, and objectives of the thesis are 
outlined.
In Chapter 2, we conducted a community-based study of 457 women from 8 
different villages in northwest Tanzania. Women were screened for S. haematobium 
and S. mansoni as well as for trichomoniasis, syphilis, and HIV infection. We 
observed a significant association between HIV and S. haematobium infection, 
with women with S. haematobium having a four-fold greater odds of being 
HIV-infected than women without S. haematobium. This finding independently 
confirmed results from a single other study done in Zimbabwe, which reported 
a similar odds ratio for HIV infection among women with S. haematobium. 
Taken together, these two studies argue strongly for the urgency of additional 
work to determine prospectively whether S. haematobium is a risk factor for HIV 
acquisition, as well as whether efforts to control S. haematobium infection will 
decrease the incidence of HIV in endemic communities.
Chapter 3 describes a similar community-based study of 345 women living in 
communities in which S. mansoni is endemic. Women received HIV voluntary 
counseling and testing and had schistosome Circulating Anodic Antigen (CAA) 
quantitated in their serum. We found that over 50% of women had schistosome 
infections. In this population, the odds of HIV infection among those with S. 
mansoni infection was 3.9. Moreover, the prevalence of HIV was highest (12.5%) 
among women with the highest quantities of CAA in serum, as compared to the 
HIV prevalence in women with light to moderate schistosome infection (8.3%) or 
the HIV prevalence among those with no detectable schistosome antigen (2.5%). 
These findings were novel, as previous studies had focused on women with S. 
haematobium, and led us to generate new hypotheses about the mechanisms of 
HIV susceptibility in women with schistosomiasis.
In Chapter 4, we explored the problem that women with urogenital schistosomiasis, 
caused by S. haematobium, had been reported to have persistent clinical disease 
even after treatment with the anti-schistosome medication praziquantel. We 
treated women with praziquantel and performed periodic follow-ups over the 
subsequent 6 months. This work expanded on prior studies by using polymerase-
chain reaction (PCR) and serum schistosome antigen measurements to quantify 
schistosome infections with increased sensitivity. We documented that, even six 
months after praziquantel treatment, women with urogenital schistosomiasis had 
persistent gynecologic abnormalities and detectable schistosome DNA in urine and 
genital specimens. This highlights the urgency of preventing gynecologic damage 
and controlling schistosomiasis early, since its effects may not be entirely reversible.
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Chapter 5 represents the laying of important groundwork that will facilitate new 
studies of schistosomiasis. We demonstrated that schistosome CAA can be eluted 
from, and quantitated in, dried blood spots, which are used widely in resource-
poor settings for both research and clinical care. CAA values obtained from 
the dried blood spots were strongly correlated with serum CAA levels, and the 
correlations remained strong even among dried blood spots that had been stored 
for 8 years. We used the Whatman ProteinSaver 903 cards for this work, which 
are the most widely-used dried blood spot collection cards worldwide. 
We then turned to interactions between HIV and schistosomiasis in Chapter 6. 
We enrolled 351 HIV-infected outpatients who had been taking antiretroviral 
therapy for at least six months. We documented that the ~30% of HIV-infected 
individuals with schistosome co-infection had a four-fold greater odds of 
immunological treatment failure than did HIV-infected individuals without 
schistosomiasis. Because many HIV-infected patients in sub-Saharan African 
are switched from first- to second-line antiretroviral treatment if they develop 
immunological failure, these findings are clinically relevant and highlight the 
critical need for additional studies in this area.
The final chapter of this thesis maintains the focus on improving HIV management 
in Tanzania, albeit via different research techniques. In Chapter 7, we present 
an implementation science study conducted to optimize the efficiency of dried 
blood spot testing for early infant diagnosis of HIV in a rural clinic in Tanzania. 
Using a series of low-cost, locally-driven interventions implemented sequentially, 
we were able to decrease the turn-around time between collection of the dried 
blood spot from the infant and the provision of the HIV test result to the patient’s 
caretaker from 55 to 38 days, and to ensure that over 90% of infants’ caretakers 
received results. This project is not only locally valuable, but is also more broadly 
applicable because it serves as a model for implementation of inexpensive, 
innovative interventions led by local healthcare staff.
The work presented in this thesis was conducted by a physician-scientist who 
both provides patient care and conducts research in Mwanza, Tanzania. Many 
of the findings have direct clinical implications for patient management and HIV 
prevention, as well as sparking essential follow-up studies to further improve 




Sinds de ontdekking van het humaan immunodeficiëntievirus hiv, ruim 35 jaar 
geleden, zijn meer dan  39 miljoen mensen overleden aan de gevolgen van een 
hiv-infectie. De hiv-epidemie heeft haar oorsprong in sub-Sahara Afrika, en nog 
steeds wordt deze regio het hardst getroffen door de gevolgen hiervan. Hoewel 
slechts 12% van de wereldbevolking zich in Afrika bevindt, woont daar tweederde 
van het aantal hiv-geïnfecteerde mensen. Daarbij is Afrika het werelddeel waar 
zich tweederde van alle nieuwe hiv- infecties ter wereld voordoen, evenals 
tweederde van het totaal aantal sterfgevallen ten gevolge van de ziekte aids.
Het is algemeen bekend dat mensen die lijden aan seksueel overdraagbare 
aandoeningen (soa’s), zoals gonorroe, syfilis, en herpes simplex-virus, een 
groter risico lopen om met hiv geïnfecteerd te raken in vergelijking tot degenen 
die vrij zijn van soa’s. Daarbij zijn de concentraties van het virus in het bloed 
veel hoger bij mensen die een hiv-infectie hebben in combinatie met een andere 
aandoening, zoals één van bovengenoemde soa’s of  tuberculose. Deze toename 
in concentratie van virusdeeltjes zorgt ervoor dat juist deze mensen met een 
dubbele infectie het virus gemakkelijker kunnen overdragen naar hun partner. 
Daarbij versnelt deze hogere concentratie de overgang van het hiv-dragerschap 
naar de symptomatische ziekte aids, en leidt het tot een snellere dood indien niet 
tijdig een behandeling wordt ingezet. Onderzoek van de laatste jaren laat steeds 
overtuigender zien dat sommige tropische parasitaire infecties ditzelfde effect 
kunnen bewerkstelligen. Met andere woorden: het lijkt er op dat co-infecties 
van hiv en parasieten een belangrijke rol spelen in de verspreiding van hiv en 
aids in sub-Sahara Afrika.
Schistosomiasis is een worminfectie waaraan naar schatting 260 miljoen 
mensen lijden, van wie 90% in sub-Sahara Afrika woont. In Tanzania, het 
land waar het onderzoek werd gedaan dat in dit proefschrift wordt beschreven, 
komen twee soorten Schistosoma endemisch voor: Schistosoma haematobium 
en S. mansoni. In sommige regio’s blijkt meer dan 50% van de volwassenen 
een infectie te hebben met ten minste één van deze twee soorten Schistosoma. 
Op zich veroorzaakt schistosomiasis al substantiële  ziekte en sterfte, met naar 
schatting 200.000 doden per jaar en een jaarlijks verlies van 3.31 miljoen DALYs 
(disability-adjusted life-years). De mogelijkheid dat schistosomiasis bovendien 
de overdracht van hiv en de progressie van aids bevordert, maakt de noodzaak 
van de juiste behandeling en bestrijding van deze verwaarloosde tropische 
worminfecties zelfs nog urgenter. 
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De focus van dit proefschrift ligt op het voorkomen van de overdracht van hiv en 
het beheersen van ziekte ten gevolge van deze infectie in sub-Sahara Afrika.  Als 
eerste zal een beschrijving worden gegeven van het uitgevoerde epidemiologische 
bevolkingsonderzoek in Tanzania, waarbij het verband  tussen infecties met hiv 
en infecties met S. haematobium en S. mansoni in kaart werd gebracht. De daarop 
volgende hoofdstukken richten zich op de behandeling van infecties met S. 
haematobium bij vrouwen, teneinde verdere genitale afwijkingen te voorkomen, 
alsmede de immunologische reacties op de behandeling bij hiv-positieve vrouwen 
gunstig te beïnvloeden. De afsluitende hoofdstukken zijn gewijd aan de mogelijke 
implementatie in Tanzania van de wetenschappelijke bevindingen met als doel 
hiv-infecties te voorkomen of in elk geval tijdig te diagnosticeren.
In Hoofdstuk 1 worden achtergrond en context belicht van het onderzoek dat 
wordt weergegeven in dit proefschrift. Tevens wordt een overzicht gegeven 
van de bestaande publicaties en worden de doelstellingen van het onderzoek 
gepresenteerd.
In Hoofdstuk 2 wordt een bevolkingsonderzoek besproken onder 457 vrouwen 
woonachtig in acht verschillende dorpen in het noordwesten van Tanzania. 
De vrouwen werden zowel onderzocht op infecties met S. haematobium en S. 
mansoni infecties, als op trichomoniasis, syfilis, en hiv. We constateerden een 
duidelijk verband tussen S. haematobium en hiv-infecties, waarbij vrouwen met 
een S. haematobium-infectie een viermaal hogere kans bleken te hebben om 
met hiv te zijn geïnfecteerd, in vergelijking tot vrouwen zonder schistosomiasis. 
Deze bevindingen bevestigen een eerdere studie in Zimbabwe waarbij 
vergelijkbare Odds Ratio’s werden gevonden voor hiv-positieve vrouwen met 
een  S. haematobium- infectie. Samen leveren deze twee onafhankelijke studies 
voldoende argumenten om prospectief vervolgonderzoek te initiëren naar de 
onderliggende mechanismen, zodat bepaald kan worden of een infectie met S. 
haematobium daadwerkelijk een risicofactor vormt  voor het oplopen van een hiv-
infectie, en tevens om aan te tonen dat bestrijding van S. haematobium zal leiden 
tot een afname van de incidentie van hiv-infecties binnen de gemeenschappen 
waar S. haematobium endemisch is.
Hoofdstuk 3 beschrijft een vergelijkbaar bevolkingsonderzoek onder 345 vrouwen 
in een gebied waar S. mansoni endemisch is. Vrouwen konden zich vrijwillig 
opgeven om zich op een hiv-infectie te laten testen, inclusief de bijbehorende 
begeleiding, en de status van hun Schistosoma-infectie te laten bepalen door 
middel van het testen op concentraties in het serum van het Circulerend 
Anodaal Antigen (CAA). Een Schistosoma-infectie werd zo bij meer dan 50% 
van de onderzochte vrouwen aangetoond, waarbij de kans op het hebben van een 
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hiv-infectie  bij de S. mansoni positieve vrouwen 3.9 keer groter bleek. Daarbij 
was de prevalentie van hiv het hoogst (12.5%) bij vrouwen die ook de hoogste 
concentratie van CAA in het serum vertoonden, terwijl de prevalentie van hiv 
8.3% was bij de vrouwen met een lage CAA- concentratie en 2.5% bij vrouwen 
bij wie dit Schistosoma antigeen niet kon worden aangetoond. Deze bevindingen 
waren nieuw aangezien voorafgaande studies zich voornamelijk waren gericht op 
infecties met S. haematobium. Dit gaf aanleiding tot nieuwe hypotheses over het 
mechanisme waardoor schistosomiasis kan leiden tot het toenemen van het risico 
op een infectie met hiv.
In Hoofdstuk 4 onderzoeken we waarom vrouwen met urogenitale schistosomiasis, 
welke wordt veroorzaakt door S. haematobium-infectie, ziekteverschijnselen 
behouden zelfs na het toedienen van de juiste behandeling met praziquantel, het 
middel tegen schistosomiasis. Hiertoe behandelden we vrouwen met praziquantel 
en gedurende de daaropvolgende zes maanden herhaalden we regelmatig de 
bepalingen. Dit onderzoek ging verder dan eerder uitgevoerde studies door het 
toepassen van nieuwe diagnostische methoden om de Schistosoma-infectie op zeer 
gevoelige wijze kwantitatief aan te tonen, te weten de polymerase kettingreactie 
(PCR) en de bepaling in het serum van het Schistosoma antigeen CAA. Hiermee 
toonden we aan dat vrouwen met urogenitale schistosomiasis aanhoudend 
gynaecologische afwijkingen vertoonden, zelfs tot zes maanden na de behandeling 
met praziquantel, en dat er tevens nog  Schistosoma DNA aantoonbaar bleek in de 
urine en de afgenomen genitaalmonsters. Deze bevindingen tonen het belang aan 
van vroegtijdige diagnostiek en behandeling van schistosomiasis, aangezien de 
gynaecologische schade in een later stadium onomkeerbaar kan zijn.
Hoofdstuk 5 legt de basis voor een nieuwe aanpak van onderzoek naar schisto-
somiasis. Hier laten we zien dat het Schistosoma antigeen CAA kan worden 
geëxtraheerd en gekwantificeerd vanuit kaartjes met ingedroogde bloeddruppels. 
Dit is een methode van verzamelen van bloedmonsters die vaak wordt toegepast 
in armere streken, zowel voor wetenschappelijke doeleinden als voor klinisch 
onderzoek. De hoeveelheid CAA, bepaald vanuit gedroogde bloedmonsters op de 
kaartjes, bleek significant te correleren met de hoeveelheid CAA die rechtstreeks 
was bepaald in het serum. Deze correlatie bleek ook niet te zijn beïnvloed als de 
kaartjes met de ingedroogde bloeddruppels tot acht jaar werden bewaard. Voor 
dit onderzoek werden Whatman ProteinSaver 903 kaartjes gebruikt, het type dat 
wereldwijd het meest wordt gebruikt voor het verzamelen van bloeddruppels.
In Hoofdstuk 6 borduren we voort op de interactie tussen hiv-infecties en 
schistosomiasis. Hierbij werden 351 hiv-positieve poliklinische patiënten 
gerekruteerd die de in de voorafgaande zes maanden antivirale behandeling 
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hadden ondergaan. We toonden aan dat de 30% van de hiv-geïnfecteerde patiënten 
die tevens een infectie met Schistosoma hadden, een vier keer zo grote kans hadden 
op immunologisch falen van de hiv-behandeling in vergelijking met diegenen 
die geen gelijktijdige Schistosoma-infectie vertoonden. Deze bevindingen zijn 
klinisch relevant omdat vele hiv-positieve patiënten in sub-Sahara Afrika van 
eerste-lijn behandeling overstappen naar een tweede-lijn behandeling  zodra 
er sprake is van een immunologisch falen. Tevens benadrukt dit hoofdstuk het 
belang van verder onderzoek naar dit onderwerp. 
Tenslotte worden in  Hoofdstuk 7 de resultaten gepresenteerd van een toegepast 
onderzoek naar het verder optimaliseren van de wijze van verzamelen en testen 
van de kaartjes met de gedroogde bloeddruppels bij pasgeborenen om daarmee 
het onderzoek naar de hiv-status in een rurale kliniek in Tanzania te verbeteren. 
Door middel van het toepassen van diverse opeenvolgende goedkope en lokaal 
aangestuurde interventies werd het mogelijk om de doorlooptijd tussen het 
verzamelen en het testen van de ‘bloedkaartjes’ terug te brengen van 55 dagen 
naar 38 dagen, waarbij er nadrukkelijk op werd gelet dat 90% van de verzorgers 
van deze kinderen ook daadwerkelijk de juiste testuitslagen ontvingen. Dit 
onderzoek was niet alleen van belang voor de lokale gemeenschap, maar is 
tevens breder toepasbaar omdat het tegemoet komt aan een algemeen model voor 
goedkope en vernieuwende interventies, voornamelijk aangestuurd door lokale 
gezondheidswerkers.
Het werk dat in dit proefschrift wordt gepresenteerd, werd uitgevoerd door 
een klinisch onderzoeker die zich in Mwanza, Tanzania, zowel bezighield 
met de patiëntenzorg als wetenschappelijk onderzoek verrichtte. Veel van de 
bevindingen zijn rechtstreeks klinisch toepasbaar, zowel in de patiëntenzorg 
als bij de preventie van hiv-infecties, maar de resultaten dienen eveneens ter 
stimulans voor vervolgstudies met als doel de gezondheidssituatie in Tanzania 
verder te verbeteren. 
Addendum  135
Acknowledgements
With deep thanks I acknowledge my collaborators, colleagues, role models, study 
team members, and partners. This thesis would not have been possible without 
the support, mentorship, and encouragement of so many people. You have been 
indispensable to my work!
First, I thank the study participants in Tanzania for your enthusiastic participation 
in our projects, your trust, and your honest answers to probing questions and 
examinations. I am inspired by you and grateful for your patience with me as I 
learn more of your culture and as we work together to learn better how to treat 
and prevent disease in Tanzania and sub-Saharan Africa.
I greatly appreciate my Tanzanian colleagues and study team members. I offer many 
thanks to the hardworking nurses (Jane Mlingi, Ndalloh Paul, Inobena Tosiri) and 
parasitologists (John Igogote, Donald Miyaye, Petro Mnyeshi, Ruth Magawa) who 
have spent long days for the past seven years working by my side in rural villages. 
I thank my physician colleagues at Bugando Medical Centre (Samuel Kalluvya, 
Adolfine Hokororo, Lucheri Efraim) and my visionary HIV clinic nurse colleague 
Sabina Manumbu for their hard work, bright ideas, and strong partnership. I also 
thank the diligent laboratory team at the National Institute for Medical Research 
(NIMR) (Julius Mngara, Donald Miyaye, Eric Lyimo, Crispin Mukerebe, Pius 
Ikigo, Peter Lutonja) for your reliable and careful work on multiple projects. I 
thank my scientific colleagues at NIMR (Godfrey Kaatano, Safari Kinung’hi, 
Jim Todd, Mark Urassa) for your wisdom and scientific advice. I am particularly 
grateful to the Director General of NIMR, John Changalucha, who has provided 
patient and wise mentorship and guidance since 2009.
I deeply thank my colleagues at Leiden University Medical Centre, who have been 
strong partners and friends since 2010. I think back fondly to the beginning of our 
partnership, when we met briefly at a meeting in Copenhagen. Shortly thereafter, 
you welcomed and taught me so much during a month in Leiden in 2011. Thank 
you to Maria Yazdanbakhsh for serving as an excellent and supportive Promotor 
and Lisette van Lieshout for serving as my dedicated Co-Promotor and close 
colleague. I am also grateful to other colleagues in the Departments of Parasitology 
(Govert van Dam, Eric Brienen, Jaco Verweij, Dieuwke Kornelis, Pytsje Hoekstra) 
and Molecular Cell Biology (Paul Corstjens, Claudia de Dood, Elisa Tjon Kon Fat) 
for all that you have taught me and for our ongoing collaborations. Special thanks 
to Pytsje Hoekstra and Claudia de Dood for also serving as my paranymphs. It is 
a pleasure to have you all as friends and colleagues. 
136  HIV and Schistosomiasis: Studies in Tanzania
I am immensely grateful to my colleagues and mentors at Weill Cornell Medical 
College. I would not be doing the work I am doing today without the strong 
support and mentorship I have received from Warren Johnson and Daniel 
Fitzgerald in the Center for Global Health. I am also grateful to Mary Charlson, 
Augustine Choi, and Trip Gulick for their support. I thank my fellow junior 
faculty colleagues and close friends Kate Dupnik, Luke Smart, and Rob Peck for 
your ongoing scientific partnership in many projects. 
Finally, I deeply thank my family. Thanks to my parents and wonderful sister for 
always encouraging me, and for visiting us in Mwanza! Thanks to my in-laws for 
your love and acceptance of your daughter-in-law, even when that means your son 
and grandchildren are far away. To my sweethearts Emily Christine (age 5), Luke 
William (age 3), and Elijah Clement (age 1)—you have lived half of your lives in 
Tanzania and patiently shared your mom with so many colleagues and patients in 
Tanzania. I adore each of you. To my darling husband—you have brought endless 
joy and love into my life for more than 20 years now, and have shaped me into the 
person I am today. Thank you.
Addendum  137
Curriculum Vitae
Jennifer Alzos Downs grew up in Wilmington, Delaware, United States of America 
and obtained her undergraduate degree from the University of North Carolina at 
Chapel Hill (Bachelor’s of Science in Biochemistry). From North Carolina, she 
moved to New York City where she obtained her Doctor of Medicine at Weill 
Cornell Medical College in 2004. During an elective rotation in rural Central 
America during medical school, she decided that she would pursue a career in 
global health.
Dr. Downs completed her internship and residency in Internal Medicine at 
Columbia University College of Physicians and Surgeons in 2007 and her 
Infectious Diseases fellowship at Weill Cornell Medical College in 2010. She made 
her first trip to Tanzania in 2007 when she worked as a resident and teacher on 
the wards at Bugando Medical Centre in Mwanza for six weeks. Following the 
completion of her clinical infectious diseases training, she returned to Mwanza 
where she established a home and gained fluency in the local language (Kiswahili).
She is currently Assistant Professor of Medicine and Assistant Professor 
of Microbiology and Immunology in the Center for Global Health at Weill 
Cornell Medical College in New York. She is also Lecturer in the Department 
of Medicine at Weill-Bugando School of Medicine in Mwanza. She devotes her 
time to research, teaching, and clinical care in Mwanza. She additionally serves 
as a teacher, mentor, and dissertation supervisor for Master’s of Medicine post-
doctoral Tanzanian students in Mwanza. She has collaborated with colleagues 
at Leiden University Medical Center since 2010 and began her PhD at LUMC in 
2014, and looks forward to continuing her work on schistosomiasis and HIV in 
Tanzania for many years to come. 
138  HIV and Schistosomiasis: Studies in Tanzania
Peer-Reviewed Publications
Downs JA, Kalluvya SE, Kataraihya JB, Jackson K, Jaka H, Kabangila R, Peck RN. 
Cranial and epidural abscesses presenting as scalp swellings in a 16-year-old 
boy: a case report.  Tanzanian Medical Journal 2009; 24:34-5.
Fusco DN, Downs JA, Satlin M, Pahuja M, Ramos L, Barie P, Fleckenstein L, Murray 
H. Non-oral treatment with ivermectin for disseminated strongyloidiasis. Am J 
Trop Med Hyg 2010; 83(4): 879-83. [PMID: 20889884]
Downs JA, Mguta C, Kaatano GM, Mitchell KB, Bang H, Simplice H, Kalluvya 
SE, Changalucha JM, Johnson WD, Fitzgerald DW. Urogenital schistosomiasis 
in women of reproductive age in Tanzania’s Lake Victoria region. Am J Trop 
Med Hyg 2011; 84(3): 364-9. [PMID: 21363971]
Msango L, Downs JA, Kalluvya SE, Kidenya BR, Kabangila R, Johnson WD, 
Fitzgerald DW, Peck RN. Renal dysfunction among HIV-infected patients 
starting antiretroviral therapy in Mwanza, Tanzania. AIDS 2011; 25: 1421-5. 
[PMID: 21572304]
Wajanga BMK, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DF, Peck RN. 
Universal Screening of Tanzanian HIV-Infected Adult Inpatients with the 
Serum Cryptococcal Antigen to Improve Diagnosis and Reduce Mortality: an 
Operational Study. J Int AIDS Society 2011 14(1):48. [PMID: 21988905]
Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA. Examining 
the relationship between urogenital schistosomiasis and HIV infection. PLoS 
Negl Trop Dis 2011 5(12): e1396. doi:10.1371/journal.pntd.0001396 [PMID: 
22163056]
Peck RN, Luhanga A, Kalluvya S, Todd J, Lugoba S, Fitzgerald DW, Downs JA. 
Predictors of tuberculosis in first six months after initiation of antiretroviral 
therapy: a case-control study. Int J Tuberc Lung Dis 2012 16(8): 1047-51. [PMID: 
22691942]
Downs JA, van Dam GJ, Changalucha JM, Corstjens PLAM, Peck RN, de Dood 
CJ, Bang H, Andreasen A, Kalluvya SE, van Lieshout L, Johnson WD, Fitzgerald 
DW. Association of schistosomiasis and HIV infection in Tanzania. Am J Trop 
Med Hyg 2012 87(5): 868-73. [PMID: 23033399]
Efraim L, Peck RN, Kalluvya SK, Kabangila R, Mazigo HM, Mpondo B, Bang HB, 
Todd J, Fitzgerald DW, Downs JA. Schistosomiasis and impaired response to 
antiretroviral therapy among HIV-infected patients in Tanzania. JAIDS 2013 
62(5):e153-e156. [PMID: 23760064]
Peck RN, Green E, Mtabaji J, Majinge C, Smart L, Downs JA, Fitzgerald DW. 
Hypertension-related diseases as a common cause of hospital mortality in 
Tanzania: a 3-year prospective study. J Hypertension 2013 31(9): 1806-11. 
[PMID: 23777761] 
Addendum  139
Downs JA, Fuunay LD, Fuunay M, Mbago M, Mwakisole A, Peck RN, Downs DJ. 
“The body we leave behind:” a qualitative study of obstacles and opportunities 
for increasing uptake of male circumcision among Tanzanian Christians. BMJ 
Open HIV/AIDS 2013 3(5). [PMID: 23793672]
Mtwangambate G, Kalluvya SE, Kidenya BR, Kabangila R,  Downs JA, Smart 
LR, Fitzgerald DW, Peck RN. ‘Cough-triggered’ tuberculosis screening among 
adults with diabetes in Tanzania. Diabet Med 2013 Oct 23. doi: 10.1111/
dme.12348. [PMID: 24152037]
Janmohamed MN, Kalluvya SE, Mueller A, Kabangila R, Smart LR, Downs JA, 
Peck RN. Prevalence of chronic kidney disease in diabetic adult outpatients in 
Tanzania. BMC Nephrol 2013 14(183). [PMID: 24228774]
Downs JA, Kabangila R, Verweij JJ, Jaka H, Peck RN, Kalluvya SE, Changalucha 
JM, Johnson WD, van Lieshout L, Fitzgerald DW. Detectable urogenital 
schistosome DNA and cervical abnormalities 6 months after single-dose 
praziquantel in women with Schistosoma haematobium infection. Trop Med 
Int Health 2013 18(9): 1090-6. [PMID: 23937701]
Wajanga BMK, Peck RN, Kalluvya SE, Fitzgerald DW, Smart LR, Downs JA. 
Healthcare worker-perceived barriers to early initiation of antiretroviral 
and tuberculosis therapy among Tanzanian inpatients. PLoS ONE 2014 Feb 
14;9(2):e87584. [PMID: 24551061]
Mpondo B, Kalluvya SE, Peck RN, Kabangila R, Kidenya B, Ephraim L, Fitzgerald 
DW, Downs JA. Impact of Antiretroviral Therapy on Renal Function among 
HIV-infected Tanzanian Adults: a Retrospective Cohort Study. PLoS ONE 2014 
Feb 26;9(2):e89573. [PMID: 24586882]
Meda JM, Kalluvya SE, Downs JA, Chofle AC, Seni J, Kidenya B, Fitzgerald 
DW, Peck RN. Cryptococcal Meningitis Management in Tanzania with Strict 
Schedule of Serial Lumber Punctures using Intravenous Tubing Sets: an 
Operational Research Study. J Acqur Immun Defic Syn 2014 Jun 1;66(2):e31-6. 
[PMID: 24675586]
Kilonzo SB, Kamugisha E, Downs JA, Kataraihya J, Onesmo R, Mheta K, Jeong 
JM, Verweij JJ, Fitzgerald DW, Peck RN. Malaria among adult inpatients in 
two Tanzanian referral hospitals: a prospective study. Acta Tropica 2014 Jun; 
134:95-100. [PMID: 24657845]
Chofle AC, Jaka H, Koy M, Smart LR, Kabangila R, Ewings FM, Mazigo HD, 
Johnson WD, Fitzgerald DW, Peck RN, Downs JA. Oesophageal varices, 
schistosomiasis, and mortality among patients admitted with haematemesis in 
Mwanza, Tanzania: a prospective cohort study. BMC Inf Dis 2014 Jun 3; 14(303). 
[PMID: 24894393]
Magambo KA, Kalluvya SE, Kapoor S, Seni J, Chofle AC, Fitzgerald DW, 
Downs JA. Utility of a Urine Lateral Flow Assay to Determine the Prevalence 
and Predictors of Cryptococcal Antigenemia in HIV-Infected Outpatients 
140  HIV and Schistosomiasis: Studies in Tanzania
Beginning Antiretroviral Therapy in Mwanza, Tanzania. J Int AIDS Soc 2014 
Aug 8; 17:19040. [PMID: 25109284]
Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthantiran M, Fitzgerald 
DW, Kataraihya JB. Hypertension, kidney disease, HIV and antiretroviral 
therapy among Tanzanian adults: a cross-sectional study. BMC Med 2014 Jul 
29; 12(1):125. [PMID: 25070128]
Downs JA, Reif L, Hokororo A, Fitzgerald DW. Increasing women in leadership 
in global health. Acad Med 2014 Aug; 89(8):1103-7. [PMID: 24918761]
Wajanga BMK, Webster LE, Peck RN, Downs JA, Mate K, Smart LR, Fitzgerald 
DW. Inpatient Mortality in sub-Saharan Africa and possible interventions: a 
mixed methods review. BMC Health Serv Res 2014  Dec 3:14(1):627. [PMID: 
25465206]
Kayange N, Smart LR, Downs JA, Maskini M, Fitzgerald DW, Peck RN. The 
influence of HIV and schistosomiasis on renal function: a cross-sectional 
study among children at a hospital in Tanzania. PLoS Negl Trop Dis 2015 Jan 
22;9(1):e0003472. [PMID: 25612312]
Hokororo A, Kihunrwa A, Kalluvya SE, Changalucha J, Fitzgerald DW, Downs 
JA. Barriers to access reproductive healthcare for pregnant adolescent girls: a 
qualitative study in Tanzania. Acta Paediatr 2015 Apr 1 [Epub ahead of print]. 
[PMID: 25473729]
Hokororo A, Kihunrwa A, Hoekstra P, Kalluvya SE, Changalucha J, Fitzgerald 
DW, Downs JA. High prevalence of sexually-transmitted infections in pregnant 
adolescent girls: a multi-community cross-sectional study. Sex Transm Infect 
2015 Apr 1 [Epub ahead of print].
Downs JA, Corstjens P, Mngara J, Lutonja P, Isingo R, Urassa M, Kornelis D, van 
Dam GJ. Correlation of serum and dried blood spot results for quantitation of 
Schistosoma circulating anodic antigen: a proof of principle. Acta Trop 2015 Jul 
3;150:59-63.
Maganga E, Smart LR, Kalluvya SE, Kataraihya JB, Saleh AM, Obeid L, Downs JA, 
Fitzgerald DW, Peck RN. Glucose metabolism disorders, HIV, and antiretroviral 
therapy among Tanzanian adults. PLoS ONE 2015 10(8):e0134410.
Kapoor S, Magambo K, Kalluvya SE, Fitzgerald DW, Peck RN, Downs JA. Six-
month outcomes of HIV-infected patients given short-course fluconazole 
therapy for asymptomatic cryptococcal antigenemia. AIDS 2015; 29(18): 2473-8.
Manumbu S, Smart LR, Mwale A, Mate KS, Downs JA. Shortening Turnaround 
Times for Newborn HIV Testing in Rural Tanzania: a Report from the Field. 
PLoS Med 2015 Nov 3; 12(11):e1001897.
Smart LR, Orgenes N, Mazigo HD, Minde M, Hokororo A, Shakir M, Verweij 
JJ, Downs JA, Peck RN. Malaria and HIV among pediatric inpatients in two 
Tanzanian referral hospitals: A prospective study. Acta Trop 2016 Mar 18; 159: 
36-43.




